



## *Can exercise and attitude change the course of PD?*

Clinical Professor David Blacker  
Medical Director Perron Institute  
Neurologist and Stroke Physician, SCGH  
Clinical Professor UWA  
Living with PD approx 15 years

# Disclosures

- Board member Parkinson's WA
- Chairperson clinical advisory committee and stockholder ARGENICA Therapeutics
- Prior talks for pharmaceutical companies sponsored medical education events
- NOT a movement disorders specialist  
DO see PD  
Adjustment to diagnosis and exercise

# Outline

## ***Can the course of PD be modulated?***

- Introduction
- Exercise- review basic terms
- Exercise as therapy
- FIGHT-PD results
- Psychological reaction to Dx
- A new image of PD
- Progression of PD
- How can we intervene?

# A neurologist with Parkinson's disease

David Blacker 

Neurology, Sir Charles Gairdner Hospital, Nedlands, Australia

**Correspondence to**  
David Blacker, Neurology, Sir Charles Gairdner Hospital, Nedlands, Western Australia 6009, Australia; david.blacker@health.wa.gov.au

Accepted 25 May 2020

I could feel Parkinson's disease creeping up on me, so when I finally summoned up the courage to have a colleague assess me and make the diagnosis, it was of no surprise; in fact, it was almost a relief.

In my mid-30s, I had taken up long-distance running, mainly to shed the weight I'd stacked on during training and fellowship years. About 10 years later, I developed a gait disturbance, manifesting as an exercise-induced dystonia in my leg. Initially, it appeared only after running a significant distance, but gradually it became more problematic, eventually leading me to stop participating in competitive events. My leg would spasm, twist and generally tighten up. I knew it was dystonia but told others it was just cramp or a 'hip problem'; that was easier than explaining what this could become.<sup>1</sup> I was otherwise fine and made a concerted effort to keep fit and to continue exercise as best I could. I also abandoned plans to reduce my caffeine intake given the possibility of this being neuroprotective in Parkinson's disease. Sadly, my sense of olfaction became impaired, so the great pleasure of the aroma of coffee was lost.

Within a few years though, other symptoms emerged, including a tremor of my right hand and leg. The first time it caused a problem was at a national conference when I stood to ask a question, and with the nervousness my hand and leg trembled. I don't think it was visible to others, but I sat quickly, shocked to realise that symptoms were making an impact.

Gradually and pervasively, more tasks became difficult. My handwriting was clearly shrinking and at work that was causing problems. The striking issue though, was bradykinesia; when demonstrating rapid alternating movements and finger tapping to patients, it was clear that my dominant hand was inferior, and

seemingly becoming slower each month. It became obvious to me that some of my Parkinson's patients were performing better than me. What really started to bother me was the impact on my ability to play golf. Generating club head speed was difficult, again related to bradykinesia. Simply walking the course was becoming a challenge, and getting a tee out of my pocket and placing the ball on it was becoming difficult.

So it was clear that it was time to get onto treatment and that I should have a proper assessment and diagnosis. I spent some time thinking about whom I should consult. I chose a respected colleague who worked in another hospital on the other side of the city. I obtained an MR scan of my brain before this and was struck by how normal it looked. I remember staring at the images, frustrated that the structure looked so normal, but the function was not.

My colleague was kind, sensitive and caring, and agreed completely with the diagnosis. With my nervousness, the tremor was there again, and he skillfully demonstrated some cogwheeling of my right arm, and the bradykinesia was there for us all to see. Straight on to L-dopa was the plan; no fiddling around with a dopamine agonist.

I filled the script for Madopar the next day and took the first tablet late that afternoon. I remember tapping my right hand and fingers to test for a response; 45 min after the dose, I could feel it working. I was almost shocked to feel this. For some reason, my expectations were low, so I felt encouraged. Over the next few days, I started to take it regularly. What I wasn't prepared for was the nausea. The worst part was the worry that this might continue. Thankfully, with time this passed and I've continued to have an excellent symptomatic response.



© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

**To cite:** Blacker D, *Pract Neurol*. Epub ahead of print: [please include Day Month Year], doi: 10.1136/practneurol-2020-002623





# Exercise and PD

## *Various lines of evidence*

- Epidemiological studies show physical activity and exercise reduce risk of PD
- Clinical observation shows that exercise can reduce motor Sx
- Animal models show appropriately timed exercise can reduce toxin induced damage of nigrostriatal dopamine system

# Rationale for endurance exercise

Lamotte et al, *Parkinson's disease* 2014

- Increased DOP metabolism
- Angiogenesis
- Neurogenesis
- Increased VO2 Max
- Neuroplasticity
- Anti-inflammatory
- Improved Mito function
- Increased brain connectivity
- Increased neurotrophic factors; BDNF, clusterin, lactated-PHE

# Definition of exercise


- *Exercise is a subcategory of physical activity that is planned, structured, repetitive and purposefully focused on improvement or maintenance of one or more components of physical fitness.*
- Non-exercise activity thermogenesis (NEAT)
- Sports
- Short bursts of vigorous physical activity

# Association of wearable device-measured vigorous intermittent lifestyle physical activity with mortality

Received: 3 March 2022

Accepted: 21 October 2022

Published online: 8 December 2022



Emmanuel Stamatakis<sup>1</sup>✉, Matthew N. Ahmadi<sup>1</sup>, Jason M. R. Gill<sup>2</sup>,  
Cecilie Thøgersen-Ntoumani<sup>3</sup>, Martin J. Gibala<sup>4</sup>, Aiden Doherty<sup>5</sup> &  
Mark Hamer<sup>6</sup>

Wearable devices can capture unexplored movement patterns such as brief bursts of vigorous intermittent lifestyle physical activity (VILPA) that is embedded into everyday life, rather than being done as leisure time exercise. Here, we examined the association of VILPA with all-cause, cardiovascular disease (CVD) and cancer mortality in 25,241 nonexercisers (mean age 61.8 years, 14,178 women/11,063 men) in the UK Biobank. Over an average follow-up of 6.9 years, during which 852 deaths occurred, VILPA was inversely associated with all three of these outcomes in a near-linear fashion. Compared with participants who engaged in no VILPA, participants who engaged in VILPA at the sample median VILPA frequency of 3 length-standardized bouts per day (lasting 1 or 2 min each) showed a 38%–40% reduction in all-cause and cancer mortality risk and a 48%–49% reduction in CVD mortality risk. Moreover, the sample median VILPA duration of 4.4 min per day was associated with a 26%–30% reduction in all-cause and cancer mortality risk and a 32%–34% reduction in CVD mortality risk. We obtained similar results when repeating the above analyses for vigorous physical activity (VPA) in 62,344 UK Biobank participants who exercised (1,552 deaths, 35,290 women/27,054 men). These results indicate that small amounts of vigorous nonexercise physical activity are associated with substantially lower mortality. VILPA in nonexercisers appears to elicit similar effects to VPA in exercisers, suggesting that VILPA may be a suitable physical activity target, especially in people not able or willing to exercise.

Physical activity is associated with reduced mortality risk<sup>1</sup>, and reduced risk of CVD<sup>2</sup> and certain cancers<sup>3–5</sup>. Recently updated guidelines<sup>6,7</sup>, based mostly on questionnaire-derived evidence, recommend 150–300 min of moderate-intensity activity or 75–150 min of vigorous-intensity physical

activity (≥6 metabolic equivalents) per week. New emphasis is placed on ‘all activity counts’ occurring across all life domains and regardless of bout duration. This recommendation contrasts with previous guidelines<sup>8,9</sup> that did not recognize the health value of physical activity bouts

<sup>1</sup>Charles Perkins Centre, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia. <sup>2</sup>School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK. <sup>3</sup>Danish Centre for Motivation and Behaviour Science, Department of Sports Science and Clinical Biomechanics, University of Southern Denmark, Odense, Denmark. <sup>4</sup>Department of Kinesiology, McMaster University, Hamilton, Ontario, Canada.

<sup>5</sup>Big Data Institute, Nuffield Department of Population Health, University of Oxford, Oxford, UK. <sup>6</sup>Institute Sport Exercise Health, Division Surgery Interventional Science, University College London, London, UK. ✉e-mail: [emmanuel.stamatakis@sydney.edu.au](mailto:emmanuel.stamatakis@sydney.edu.au)

# Main categories of exercise

- Endurance
- Strength
- Balance
- Flexibility

# More exercise definitions

- Aerobic (“with air”) ie energy metabolism using  $O_2$ , usually moderate, steady
- Anaerobic (“without air”), metabolic pathways don’t use  $O_2$ , usually high intensity and short

# Global Recommendations on Physical Activity for Health

## 65 years and above

These guidelines are relevant to all healthy adults aged 65 years and above, unless specific medical conditions indicate to the contrary, irrespective of gender, race, ethnicity or income level. They are also relevant to individuals in this age range with chronic NCD conditions or with disabilities. Individuals with specific health conditions, such as cardiovascular disease and diabetes, may need to take extra precautions and seek medical advice before trying to achieve the recommended levels of physical activity for older adults.

Strong evidence demonstrates that compared to less active men and women, older adults who are physically active have:

- lower rates of coronary heart disease, hypertension, stroke, diabetes, colon and breast cancer, a higher level of cardiorespiratory and muscular fitness,
- healthier body mass and composition and enhanced bone health; and
- higher levels of functional health, a lower risk of falling, and better cognitive function.

### Recommendations:

In older adults of the 65 years and above age group, physical activity includes leisure time physical activity, transportation (e.g. walking or cycling), occupational (if the individual is still engaged in work), household chores, play, games, sports or planned exercise, in the context of daily, family, and community activities. The recommendations in order to improve cardiorespiratory and muscular fitness, bone and functional health, reduce the risk of NCDs, depression and cognitive decline are:

1. Older adults should do at least 150 minutes of moderate-intensity aerobic physical activity throughout the week or do at least 75 minutes of vigorous-intensity aerobic physical activity throughout the week or an equivalent combination of moderate- and vigorous-intensity activity.
2. Aerobic activity should be performed in bouts of at least 10 minutes duration.
3. For additional health benefits, older adults should increase their moderate-intensity aerobic physical activity to 300 minutes per week, or engage in 150 minutes of vigorous-intensity aerobic physical activity per week, or an equivalent combination of moderate- and vigorous-intensity activity.
4. Older adults, with poor mobility, should perform physical activity to enhance balance and prevent falls on 3 or more days per week.
5. Muscle-strengthening activities, involving major muscle groups, should be done on 2 or more days a week.
6. When older adults cannot do the recommended amounts of physical activity due to health conditions, they should be as physically active as their abilities and conditions allow.

Inactive people should start with small amounts of physical activity and gradually increase duration, frequency and intensity over time. Inactive adults and those with disease limitations will have added health benefits when they become more active.

For further information see: <http://www.who.int/dietphysicalactivity/pa/en/index.html>  
or contact WHO on [dietandhealth@who.int](mailto:dietandhealth@who.int)





# Measuring exercise and exercise intensity

## Lab based

- VO2 max, lactate thresholds

## Field based

Heart rate based

Some studies report % of maximum HR, other % heart rate reserve (some both)

Max HR, Karnoven equation;  $220 - \text{age}$

Heart rate reserve (HRR);  $\text{Max HR} - \text{resting HR}$

HRR used to calculate HR defined exercise zones

Target HR intensity=

$(\text{Max} - \text{resting} \times \text{intensity}) + \text{resting HR}$

Moderate ; 50-70%

High; 70-85%

“High intensity” also defined  $> 80\%$  max HR

# Scales and Questionnaires

- ♦ Baseline
- ♦ Before each exercise session
- ♦ During the exercise session
- ♦ After the exercise session
- ♦ End of 5 week block
- ♦ End of the 15 week programme

**Borg's Rating of Perceived Exertion (RPE) Scale**

Perceived Exertion Rating	Description of Exertion
6	No exertion. Sitting & resting
7	Extremely light
8	
9	Very light
10	
11	Light
12	
13	Somewhat hard
14	
15	Hard
16	
17	Very hard
18	
19	Extremely hard
20	Maximal exertion

[https://www.braininjuryaustralia.org.au/wp-content/uploads/Barry-Willer\\_2.pdf](https://www.braininjuryaustralia.org.au/wp-content/uploads/Barry-Willer_2.pdf)

# High intensity interval training

## HIIT

- **HIIT** Form of interval training where short periods (<20 sec) of near maximal effort are mixed with rest
- Intense anaerobic exercise
- ***HIIT may be the threshold for triggering the release of BDNF and other metabolic factors?***
- ***Goal directed practice + aerobic (better still HIT) synergistic to facilitate neuroplasticity***

Taking blood from mice who run and infusing into sedentary mice improves cognition and reduces neuroinflammation



# Exercise plasma boosts memory and dampens brain inflammation via clusterin

<https://doi.org/10.1038/s41586-021-04183-x>

Received: 26 July 2019

Accepted: 26 October 2021

Published online: 8 December 2021

 Check for updates

Zurine De Miguel<sup>1,2,3,11</sup>, Nathalie Khoury<sup>1,2,3,14</sup>, Michael J. Betley<sup>1,4,14</sup>, Benoit Lehallier<sup>1,2,3,12</sup>, Drew Willoughby<sup>1,2,3</sup>, Niclas Olsson<sup>5,13</sup>, Andrew C. Yang<sup>1,2,3</sup>, Oliver Hahn<sup>1,2,3</sup>, Nannan Lu<sup>1,2,3</sup>, Ryan T. Vest<sup>1,2,3</sup>, Liana N. Bonanno<sup>1,2,3</sup>, Lakshmi Yerra<sup>6</sup>, Lichao Zhang<sup>7</sup>, Nay Lui Saw<sup>8</sup>, J. Kaci Fairchild<sup>9</sup>, Davis Lee<sup>1,2,3</sup>, Hui Zhang<sup>1,2,3</sup>, Patrick L. McAlpine<sup>9</sup>, Kévin Contrepois<sup>10</sup>, Mehrdad Shamloo<sup>8</sup>, Joshua E. Elias<sup>5,7</sup>, Thomas A. Rando<sup>1,2,6</sup> & Tony Wyss-Coray<sup>1,2,3,12</sup>✉

Physical exercise is generally beneficial to all aspects of human and animal health, slowing cognitive ageing and neurodegeneration<sup>1</sup>. The cognitive benefits of physical exercise are tied to an increased plasticity and reduced inflammation within the hippocampus<sup>2–4</sup>, yet little is known about the factors and mechanisms that mediate these effects. Here we show that ‘runner plasma’, collected from voluntarily running mice and infused into sedentary mice, reduces baseline neuroinflammatory gene expression and experimentally induced brain inflammation. Plasma proteomic analysis revealed a concerted increase in complement cascade inhibitors including clusterin (CLU). Intravenously injected CLU binds to brain endothelial cells and reduces neuroinflammatory gene expression in a mouse model of acute brain inflammation and a mouse model of Alzheimer’s disease. Patients with cognitive impairment who participated in structured exercise for 6 months had higher plasma levels of CLU. These findings demonstrate the existence of anti-inflammatory exercise factors that are transferrable, target the cerebrovasculature and benefit the brain, and are present in humans who engage in exercise.

Physical activity evokes profound physiological responses in multiple tissues across the animal kingdom and is accepted to broadly improve human health<sup>1,5</sup>. The benefits of exercise extend to patients with neurodegeneration and brain trauma<sup>6,7</sup>, possibly by reducing neuroinflammation<sup>2</sup>. Long-term voluntary exercise in mouse models of Alzheimer’s disease (AD) and related disorders improve learning and memory, and decrease neuroinflammation<sup>3,7,8</sup>. How exercise exerts these beneficial effects is poorly understood. It has been proposed that ‘exercise factors’—secreted from muscle and other tissues into the blood—subsequently signal to the brain. Factors including IGF-1 (ref. <sup>9</sup>), VEGF<sup>10</sup> and PF4 (ref. <sup>11</sup>) increase hippocampal neurogenesis in young mice, whereas GPD1L rescues the age-related loss in neurogenesis and cognition in old mice<sup>12</sup> (Extended Data Table 1). However, it is unknown whether exercise-conditioned plasma contains factors that benefit the young healthy brain, whether these factors are directly transferrable through the plasma, whether such factors mediate the anti-inflammatory effect of exercise and what the key factors are.

## Runner plasma improves cognition

Given these beneficial effects of exercise on the hippocampus, we investigated whether plasma from exercising male mice (runner

plasma (RP)) transferred into young non-exercising littermates can mimic running; mice without access to a running wheel in their cage generated control plasma (CP) (Fig. 1a; details of the set-up are provided in the Methods). We observed that 28 d of running was sufficient to increase overall cell survival (BrdU<sup>+</sup> cells), including neurons (NeuN<sup>+</sup> BrdU<sup>+</sup> cells), the number of neural stem and progenitor cells (NSPCs; Sox2<sup>+</sup> GFAP<sup>+</sup> cells) and astrocytes (GFAP<sup>+</sup> BrdU<sup>+</sup> cells) and that this effect was most prominent in mice aged 3 months (Extended Data Fig. 1a–d). Notably, recipient mice that received RP showed a significant increase in total proliferating cells, DCX<sup>+</sup> neuroblasts and surviving cells compared with CP-recipient mice (Fig. 1b, c). Notably, these results are very similar to the direct effects of running described above (Extended Data Fig. 1a–d). Importantly, repeated control injections of saline through the retro-orbital vein under anaesthesia did not significantly alter hippocampal cell proliferation and survival, whereas restraining mice and injecting them through the tail vein reduced proliferation (Extended Data Fig. 1e). Furthermore, RP induced a twofold expansion of surviving NSPCs compared with CP. However, RP did not significantly increase the number of surviving mature neurons and, instead, lead to a twofold increase in the survival of newly produced astrocytes (Fig. 1c). In an independent experiment, RP from mice that had access to a running wheel for 28 d replicated

<sup>1</sup>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA. <sup>2</sup>Glenn Center for the Biology of Aging, Stanford University School of Medicine, Stanford, CA, USA. <sup>3</sup>Wu Tsai Neurosciences Institute, Stanford University, Stanford, CA, USA. <sup>4</sup>Neurosciences Graduate Training Program, Stanford University School of Medicine, Stanford, CA, USA. <sup>5</sup>Department of Chemical and Systems Biology, Stanford University School of Medicine, Stanford, CA, USA. <sup>6</sup>The Veterans Affairs Palo Alto HealthCare System, Palo Alto, CA, USA. <sup>7</sup>Chan Zuckerberg Biohub, Stanford, CA, USA. <sup>8</sup>Behavioral and Functional Neuroscience Laboratory, Stanford University School of Medicine, Stanford, CA, USA. <sup>9</sup>Otolaryngology Head and Neck Surgery Research Division, Stanford University, Stanford, CA, USA. <sup>10</sup>Department of Genetics, Stanford University, Stanford, CA, USA. <sup>11</sup>Present address: Psychology Department, California State University, Monterey Bay, CA, USA. <sup>12</sup>Present address: Alkermes Inc, San Carlos, CA, USA. <sup>13</sup>Present address: Calico Life Sciences, South San Francisco, CA, USA. <sup>14</sup>These authors contributed equally: Nathalie Khoury, Michael J. Betley. ✉e-mail: [two@stanford.edu](mailto:two@stanford.edu)

# An exercise-inducible metabolite that suppresses feeding and obesity

<https://doi.org/10.1038/s41586-022-04828-5>

Received: 15 July 2021

Accepted: 3 May 2022

Published online: 15 June 2022

 Check for updates

Veronica L. Li<sup>1,2,3,18,20</sup>, Yang He<sup>4,20</sup>, Kévin Contrepois<sup>5,6,7</sup>, Hailan Liu<sup>4</sup>, Joon T. Kim<sup>1,3</sup>, Amanda L. Wiggenhorn<sup>1,2,3</sup>, Julia T. Tanzo<sup>1,3</sup>, Alan Sheng-Hwa Tung<sup>1,3</sup>, Xuchao Lyu<sup>1,3,19</sup>, Peter-James H. Zushin<sup>8</sup>, Robert S. Jansen<sup>9,10</sup>, Basil Michael<sup>9</sup>, Kang Yong Loh<sup>2,3</sup>, Andrew C. Yang<sup>11</sup>, Christian S. Carl<sup>12</sup>, Christian T. Voldstedlund<sup>12</sup>, Wei Wei<sup>1,3,13</sup>, Stephanie M. Terrell<sup>1,3</sup>, Benjamin C. Moeller<sup>14,15</sup>, Rick M. Arthur<sup>15</sup>, Gareth A. Wallis<sup>16</sup>, Koen van de Wetering<sup>8,17</sup>, Andreas Stahl<sup>8</sup>, Bente Kiens<sup>12</sup>, Erik A. Richter<sup>12</sup>, Steven M. Banik<sup>2,3</sup>, Michael P. Snyder<sup>5,6,7,19</sup>, Yong Xu<sup>4,18,20</sup> & Jonathan Z. Long<sup>1,3,6,7,19</sup>✉

Exercise confers protection against obesity, type 2 diabetes and other cardiometabolic diseases<sup>1–3</sup>. However, the molecular and cellular mechanisms that mediate the metabolic benefits of physical activity remain unclear<sup>4</sup>. Here we show that exercise stimulates the production of *N*-lactoyl-phenylalanine (Lac-Phe), a blood-borne signalling metabolite that suppresses feeding and obesity. The biosynthesis of Lac-Phe from lactate and phenylalanine occurs in CNDP2<sup>+</sup> cells, including macrophages, monocytes and other immune and epithelial cells localized to diverse organs. In diet-induced obese mice, pharmacological-mediated increases in Lac-Phe reduces food intake without affecting movement or energy expenditure. Chronic administration of Lac-Phe decreases adiposity and body weight and improves glucose homeostasis. Conversely, genetic ablation of Lac-Phe biosynthesis in mice increases food intake and obesity following exercise training. Last, large activity-inducible increases in circulating Lac-Phe are also observed in humans and racehorses, establishing this metabolite as a mammalian effector associated with physical activity across multiple activity modalities and mammalian species. These data define a conserved exercise-inducible metabolite that controls food intake and influences systemic energy balance.

Exercise is a powerful physiological intervention that protects against obesity and obesity-associated cardiometabolic diseases<sup>1–3</sup>. By contrast, physical inactivity increases the risk of obesity, metabolic disease and all-cause mortality<sup>4,5</sup>. There has been a growing interest in identifying ‘molecular transducers’ that might mediate the cardiometabolic benefits of exercise<sup>6</sup>. Although large-scale multi-omics efforts (for example, by the Molecular Transducers of Physical Activity Consortium) have begun to generate molecular maps of the biological molecules regulated by physical activity<sup>6–9</sup>, the functional relationships between these molecular changes and physiological outcomes remain poorly defined. In parallel, candidate approaches have uncovered specific functional exercise-regulated signalling molecules<sup>10–14</sup>, but the extent to which these candidate molecules represent the most important mediators of physical activity remains unclear. We reasoned that a hybrid approach might be valuable in both providing a global view of the most relevant

molecular changes associated with physical activity and designating high-priority, candidate molecular transducers of exercise.


## Plasma metabolomics of exercise


To measure exercise-induced circulating metabolites in a global and unbiased manner, we performed both targeted and untargeted metabolomics of blood plasma from mice following an acute bout of treadmill running until exhaustion (Extended Data Fig. 1a). Our targeted metabolomics analysis detected increases in several metabolites, including lactate, fumarate and succinate, which were previously established to be regulated by physical activity<sup>6–8,12,15,16</sup> (Fig. 1a, Supplementary Table 1 and Methods). The metabolite most significantly induced by exercise, however, was found by untargeted metabolomics (Fig. 1a,b). This metabolite had a mass-to-charge ratio (*m/z*) of 236.0928 that was

<sup>1</sup>Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA. <sup>2</sup>Department of Chemistry, Stanford University, Stanford, CA, USA. <sup>3</sup>Sarafan ChEM-H, Stanford University, Stanford, CA, USA. <sup>4</sup>Children’s Nutrition Research Center, Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA. <sup>5</sup>Department of Genetics, Stanford University School of Medicine, Stanford, CA, USA. <sup>6</sup>Stanford Cardiovascular Institute, Stanford University, Stanford, CA, USA. <sup>7</sup>Stanford Diabetes Research Center, Stanford University, Stanford, CA, USA.

<sup>8</sup>Department of Nutrition and Toxicology, University of California Berkeley, Berkeley, CA, USA. <sup>9</sup>Netherlands Cancer Institute, Amsterdam, Netherlands. <sup>10</sup>Department of Microbiology, Radboud University, Nijmegen, Netherlands. <sup>11</sup>Department of Anatomy and the Bakar Aging Research Institute, University of California San Francisco, San Francisco, CA, USA. <sup>12</sup>August Krogh Section of Molecular Physiology, Department of Nutrition, Exercise and Sports, Faculty of Science, University of Copenhagen, Copenhagen, Denmark. <sup>13</sup>Department of Biology, Stanford University, Stanford, CA, USA. <sup>14</sup>Maddy Equine Analytical Chemistry Laboratory, California Animal Health and Food Safety Laboratory, School of Veterinary Medicine, University of California at Davis, Davis, CA, USA. <sup>15</sup>Department of Molecular Biosciences, School of Veterinary Medicine, University of California, Davis, CA, USA. <sup>16</sup>School of Sport, Exercise, and Rehabilitation Sciences, College of Life and Environmental Sciences, University of Birmingham, Birmingham, UK. <sup>17</sup>Department of Dermatology and Cutaneous Biology, Thomas Jefferson University, Philadelphia, PA, USA.

<sup>18</sup>Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA. <sup>19</sup>Wu Tsai Human Performance Alliance, Stanford University, Stanford, CA, USA. <sup>20</sup>These authors contributed equally: Veronica L. Li, Yang He. ✉e-mail: yongxu@bcm.edu; jzlong@stanford.edu





**Fig. 1.** Bilateral tapping task activation t-score and mean percent signal change (Pct) in each of the 3 states, averaged across patients and shown on Talairach-averaged anatomy. Activation t-score (**top**) was thresholded at 3.5 sigma. Pct (**bottom**) was masked by activation thresholded at 2 sigma.

MEDS + FE, compared to OFF MEDS. Overall, medication improved UPDRS-III ratings by 37% while UPDRS-III ratings improved by 48% in the OFF MEDS + FE relative to OFF MEDS (Table 2).

Analysis of variance (ANOVA) indicated significant difference in

UPDRS Motor III scores among the conditions (ON MEDS, OFF MEDS, OFF MEDS + FE) ( $F_{2,23} = 14.78$ ;  $P < 0.001$ , Fig. 2A). Post-hoc Tukey testing demonstrated that UPDRS-III ratings were significantly ( $P < 0.001$ ) improved when comparing ON MEDS to OFF



# Clinical studies

# Phase 2 exercise studies in PD

Title Author year	# subjects	Stage of PD UPDRS III	Inter- vention	Intensity	Volume Duration	Result UPDRS motor change
SPARX 2 Schenkman <i>JAMA</i> 2018	<u>128</u> 43 HI 45 MI 40 cont	H&Y 1 or 2 < 5 years NO meds Exercise < 3 p/ week 17,16,16	Treadmill walking	HI 80-85% MI 40 control	Aimed for 4 days p/week 2.8 HI 3.2 MI	HI +0.3 MI +3.2 (p=0.03)
PARK-In SHAPE Van der Kolk, Bloem <i>Lancet N</i> 2019	<u>130</u> 65 active 65 cont	H&Y 1 or 2 3.2 yeqrs post Dx Stable therapy 29.5 active 27.2 cont	Stationary cycle v stretching	Ave % max HR 76%	3 per week 30-45 min 6 months	Active +1.3 Cont +5.6 MRI substudy
RCT walking Mak et al <i>Journal of PD</i> 2021	<u>64</u> 33 active 31 cont	H&Y 2 Ave 2 years 29.7 active 28.7 cont	Outdoor brisk walking	"Moderate" 40-60% HRR	3 per week 60-90 mins 6 months	Active -6.0 Cont -1.4  NB ave +4.7 CID = + 4.6 CID = - 3.3

# Effect of High-Intensity Treadmill Exercise on Motor Symptoms in Patients With De Novo Parkinson Disease

## A Phase 2 Randomized Clinical Trial

Margaret Schenkman, PhD, PT; Charity G. Moore, PhD; Wendy M. Kohrt, PhD; Deborah A. Hall, MD, PhD; Anthony Delitto, PhD, PT; Cynthia L. Comella, MD; Deborah A. Josbeno, PT, PhD; Cory L. Christiansen, PhD, PT; Brian D. Berman, MD, MS; Benzi M. Kluger, MD; Edward L. Melanson, PhD; Samay Jain, MD; Julie A. Robichaud, BS-PT, MHS, PhD; Cynthia Poon, PhD; Daniel M. Corcos, PhD

 [Supplemental content](#)

**IMPORTANCE** Parkinson disease is a progressive neurologic disorder. Limited evidence suggests endurance exercise modifies disease severity, particularly high-intensity exercise.

**OBJECTIVES** To examine the feasibility and safety of high-intensity treadmill exercise in patients with de novo Parkinson disease who are not taking medication and whether the effect on motor symptoms warrants a phase 3 trial.

**DESIGN, SETTING, AND PARTICIPANTS** The Study in Parkinson Disease of Exercise (SPARX) was a phase 2, multicenter randomized clinical trial with 3 groups and masked assessors. Individuals from outpatient and community-based clinics were enrolled from May 1, 2012, through November 30, 2015, with the primary end point at 6 months. Individuals with idiopathic Parkinson disease (Hoehn and Yahr stages 1 or 2) aged 40 to 80 years within 5 years of diagnosis who were not exercising at moderate intensity greater than 3 times per week and not expected to need dopaminergic medication within 6 months participated in this study. A total of 384 volunteers were screened by telephone; 128 were randomly assigned to 1 of 3 groups (high-intensity exercise, moderate-intensity exercise, or control).

**INTERVENTIONS** High-intensity treadmill exercise (4 days per week, 80%-85% maximum heart rate [ $n = 43$ ]), moderate-intensity treadmill exercise (4 days per week, 60%-65% maximum heart rate [ $n = 45$ ]), or wait-list control ( $n = 40$ ) for 6 months.

**MAIN OUTCOMES AND MEASURES** Feasibility measures were adherence to prescribed heart rate and exercise frequency of 3 days per week and safety. The clinical outcome was 6-month change in Unified Parkinson's Disease Rating Scale motor score.

**RESULTS** A total of 128 patients were included in the study (mean [SD] age, 64 [9] years; age range, 40-80 years; 73 [57.0%] male; and 108 [84.4%] non-Hispanic white). Exercise rates were 2.8 (95% CI, 2.4-3.2) days per week at 80.2% (95% CI, 78.8%-81.7%) maximum heart rate in the high-intensity group and 3.2 (95% CI, 2.8-3.6;  $P = .13$ ) days per week at 65.9% (95% CI, 64.2%-67.7%) maximum heart rate in the moderate-intensity group ( $P < .001$ ). The mean change in Unified Parkinson's Disease Rating Scale motor score in the high-intensity group was 0.3 (95% CI, -1.7 to 2.3) compared with 3.2 (95% CI, 1.4 to 5.1) in the usual care group ( $P = .03$ ). The high-intensity group, but not the moderate-intensity group, reached the predefined nonutility threshold compared with the control group. Anticipated adverse musculoskeletal events were not severe.

**CONCLUSIONS AND RELEVANCE** High-intensity treadmill exercise may be feasible and prescribed safely for patients with Parkinson disease. An efficacy trial is warranted to determine whether high-intensity treadmill exercise produces meaningful clinical benefits in de novo Parkinson disease.

**TRIAL REGISTRATION** [clinicaltrials.gov](https://clinicaltrials.gov) Identifier: NCT01506479

JAMA Neurol. 2018;75(2):219-226. doi:10.1001/jamaneurol.2017.3517  
Published online December 11, 2017.

**Author Affiliations:** Author affiliations are listed at the end of this article.

**Corresponding Author:** Margaret Schenkman, PhD, PT, Physical Therapy Program, School of Medicine, University of Colorado Anschutz Medical Campus, 13121 E 17th Ave, Markstop C244, Aurora, CO 80045 (margaret.schenkman@ucdenver.edu).

## Research Report

---

# Six-Month Community-Based Brisk Walking and Balance Exercise Alleviates Motor Symptoms and Promotes Functions in People with Parkinson's Disease: A Randomized Controlled Trial

Margaret K.Y. Mak\* and Irene S.K. Wong-Yu

*Department of Rehabilitation Sciences, The Hong Kong Polytechnic University, Hong Kong SAR, China*

Accepted 12 April 2021

Pre-press 3 May 2021

### Abstract.

**Background:** In Parkinson's disease (PD), sustained aerobic exercise is a promising therapy in delaying motor disability. Brisk walking is a moderate intensity aerobic training, which could be translated to community practice at low cost, but its effects on motor symptoms remains unclear.

**Objective:** To determine the effectiveness of a six-month brisk walking and balance program in alleviating motor symptoms, and promoting functional, gait, and balance performance in people with PD.

**Methods:** Seventy individuals with mild to moderate PD were randomly assigned to a brisk walking (BW) group or an active control (CON) group. BW group received ten 90-minute supervised brisk walking and balance exercise for six months (weeks 1–6: once/week, weeks 7–26: once/month). CON group received upper limb training. Both groups performed 2–3 self-practice sessions weekly. Primary outcome was Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) motor score. Secondary outcomes were fast gait speed (FGS), timed-up-and-go (TUG) time, six-minute walk distance (6MWD), and Mini-Balance Evaluation Systems Test (Mini-BEST) score.

**Results:** Sixty-four participants (33 BW/31 CON) completed training. BW group showed greater significant decreases from baseline than CON group in MDS-UPDRS motor score after six weeks ( $-5.5$  vs  $-1.6$ ,  $p < 0.001$ ) and 6 months ( $-6.0$  vs  $-1.4$ ,  $p < 0.001$ ) of training. BW group also showed greater significant improvement from the baseline than CON group for TUG time, FGS, 6MWD, and mini-BEST score (all  $p < 0.05$ ).

**Conclusion:** The six-month brisk walking and balance program alleviates motor symptoms, promotes functional and gait performance, walking capacity, and dynamic balance in people with mild to moderate PD.

Keywords: Parkinson's disease, rehabilitation, aerobic exercise, recovery of function, postural balance

## INTRODUCTION

Parkinson's disease (PD) is a chronic progressive disorder affecting around seven million people in the year 2020 [1], characterized by motor symptoms including bradykinesia, rigidity, tremor, and postural

---

\*Correspondence to: Margaret K.Y. Mak, PhD, Professor, Department of Rehabilitation Sciences, The Hong Kong Polytechnic University, Hung Hom, Hong Kong SAR, China. Tel.: +852 2766 6708; Fax: +852 2330 8656; E-mail: margaret.mak@polyu.edu.hk.



# Effectiveness of home-based and remotely supervised aerobic exercise in Parkinson's disease: a double-blind, randomised controlled trial

Nicolien M van der Kolk, Nienke M de Vries, Roy P C Kessels, Hilde Joosten, Aeilko H Zwinderman, Bart Post, Bastiaan R Bloem

*Lancet Neurol* 2019;  
18: 998–1008

Published Online  
September 11, 2019  
[http://dx.doi.org/10.1016/S1473-4422\(19\)30285-6](http://dx.doi.org/10.1016/S1473-4422(19)30285-6)

See [Comment](#) page 982

Donders Institute for Brain, Cognition, and Behavior and Department of Neurology, Center of Expertise for Parkinson & Movement Disorders (N M van der Kolk MD, N M de Vries PhD, B Post MD, Prof B R Bloem MD), Department of Medical Psychology & Radboudumc Alzheimer Center (R P C Kessels PhD), Radboud University Medical Center, Nijmegen, Netherlands; Canisius Wilhelmina Hospital, Department of Sports Medicine, Nijmegen, Netherlands (H Joosten MD); and Amsterdam University Medical Centers, Clinical Epidemiology & Biostatistics, Amsterdam, Netherlands (A H Zwinderman PhD)

Correspondence to: Prof Bastiaan R Bloem, Department of Neurology, Center of Expertise for Parkinson & Movement Disorders, Radboud University Medical Centre, 6500 HB Nijmegen, Netherlands  
[bas.bloem@radboudumc.nl](mailto:bas.bloem@radboudumc.nl)

## Summary

**Background** High-intensity aerobic exercise might attenuate the symptoms of Parkinson's disease, but high-quality evidence is scarce. Moreover, long-term adherence remains challenging. We aimed to evaluate the effectiveness of aerobic exercise—gamified and delivered at home, to promote adherence—on relieving motor symptoms in patients with Parkinson's disease with mild disease severity who were on common treatment regimes.

**Methods** In this single-centre, double-blind, randomised controlled trial (Park-in-Shape), we recruited sedentary patients with Parkinson's disease from the outpatient clinic at Radboudumc, Nijmegen, Netherlands. Patients were made aware of the study either by their treating neurologist or via information in the waiting room. Patients could also contact the study team via social media. We included patients aged 30–75 years with a Hoehn and Yahr stage of 2 or lower, who were on stable dopaminergic medication. Patients were randomly assigned (in a 1:1 ratio) to either aerobic exercise done on a stationary home-trainer (aerobic intervention group) or stretching (active control group) by means of a web-based system with minimisation for sex and medication status (treated or untreated) and permuted blocks of varying sizes of more than two (unknown to study personnel). Patients were only aware of the content of their assigned programme. Assessors were unaware of group assignments. Both interventions were home based, requiring 30–45 min training three times per week for 6 months. Both groups received a motivational app and remote supervision. Home trainers were enhanced with virtual reality software and real-life videos providing a so-called exergaming experience (ie, exercise enhanced by gamified elements). The primary outcome was the between-group difference in the Movement Disorders Society—Unified Parkinson's Disease Rating Scale (MDS-UPDRS) motor section at 6 months, tested during the off state ( $\geq 12$  h after last dopaminergic medication). The analysis was done on an intention-to-treat basis in patients who completed the follow-up assessment, regardless of whether they completed the assigned intervention. Patients reported adverse events directly to their coach and also after the 6-month visit retrospectively. A between-group difference of 3–5 points or more was deemed a-priori clinically relevant. The study is concluded and registered with the Dutch Trial Registry, NTR4743.

**Findings** Between Feb 2, 2015, and Oct 27, 2017, 139 patients were assessed for eligibility in person, of whom 130 were randomly assigned to either the aerobic intervention group (n=65) or the active control group (n=65). Data from 125 (96%) patients were available for the primary analysis; five patients were lost to follow-up (four in the intervention group; one in the control group). 20 patients (ten in each group) did not complete their assigned programme. The off-state MDS-UPDRS motor score revealed a between-group difference of 4·2 points (95% CI 1·6–6·9,  $p=0\cdot0020$ ) in favour of aerobic exercise (mean 1·3 points [SE 1·8] in the intervention group and 5·6 points [SE 1·9] for the control group). 11 patients had potentially related adverse events (seven [11%] in the intervention group, four [6%] in the control group) and seven had unrelated serious adverse events (three in the intervention group [vestibular disorder, vasovagal collapse, knee injury during gardening that required surgery; 6%], four in the control group [supraventricular tachycardia, hip fracture, fall related injury, severe dyskinesias after supratherapeutic dose levodopa in a patient with deep brain stimulation; 7%]).

**Interpretation** Aerobic exercise can be done at home by patients with Parkinson's disease with mild disease severity and it attenuates off-state motor signs. Future studies should establish long-term effectiveness and possible disease-modifying effects.

**Funding** Netherlands Organization for Health Research and Development.



**Copyright** © 2019 Elsevier Ltd. All rights reserved.

## Introduction



Parkinson's disease is a progressive neurodegenerative disorder.<sup>1</sup> Pharmacotherapy alleviates symptoms but is limited by response fluctuations with disease progression.<sup>2</sup>

Non-pharmacological approaches might offer additional symptomatic relief. High-intensity aerobic exercise appears to be promising with beneficial effects on several functional outcomes (that were often specifically trained

# Aerobic Exercise Alters Brain Function and Structure in Parkinson's Disease: A Randomized Controlled Trial

Martin E. Johansson, MSc <sup>1,2†</sup> Ian G. M. Cameron, PhD <sup>3,4,5†</sup>

Nicolien M. Van der Kolk, MD, PhD <sup>2</sup> Nienke M. de Vries, PhD <sup>2</sup> Eva Klimars, MSc,<sup>1,2</sup>

Ivan Toni, PhD <sup>1</sup> Bastiaan R. Bloem, MD, PhD,<sup>2</sup> and Rick C. Helmich, MD, PhD <sup>1,2</sup>

**Objective:** Randomized clinical trials have shown that aerobic exercise attenuates motor symptom progression in Parkinson's disease, but the underlying neural mechanisms are unclear. Here, we investigated how aerobic exercise influences disease-related functional and structural changes in the corticostriatal sensorimotor network, which is involved in the emergence of motor deficits in Parkinson's disease. Additionally, we explored effects of aerobic exercise on tissue integrity of the substantia nigra, and on behavioral and cerebral indices of cognitive control.

**Methods:** The Park-in-Shape trial is a single-center, double-blind randomized controlled trial in 130 Parkinson's disease patients who were randomly assigned (1:1 ratio) to aerobic exercise (stationary home trainer) or stretching (active control) interventions (duration = 6 months). An unselected subset from this trial (exercise,  $n = 25$ ; stretching,  $n = 31$ ) underwent resting-state functional and structural magnetic resonance imaging (MRI), and an oculomotor cognitive control task (pro- and antisaccades), at baseline and at 6-month follow-up.

**Results:** Aerobic exercise, but not stretching, led to increased functional connectivity of the anterior putamen with the sensorimotor cortex relative to the posterior putamen. Behaviorally, aerobic exercise also improved cognitive control. Furthermore, aerobic exercise increased functional connectivity in the right frontoparietal network, proportionally to fitness improvements, and it reduced global brain atrophy.

**Interpretation:** MRI, clinical, and behavioral results converge toward the conclusion that aerobic exercise stabilizes disease progression in the corticostriatal sensorimotor network and enhances cognitive performance.

ANN NEUROL 2022;91:203–216

An increasing number of studies suggest that motor symptoms associated with Parkinson's disease (PD) can be improved through physical exercise. We recently completed a clinical trial showing attenuated motor symptom progression in PD following an aerobic exercise intervention (Park-in-Shape trial).<sup>1</sup> Similar findings were observed in a

clinical trial that investigated exercise dosage in de novo PD (SPARX trial).<sup>2</sup> These two studies provide strong clinical evidence that exercise can alleviate motor symptoms in PD. However, the cerebral mechanisms underlying this effect remain unclear. Here, we investigated the effect of aerobic exercise on cerebral changes using longitudinal,

View this article online at [wileyonlinelibrary.com](https://onlinelibrary.wiley.com/doi/10.1002/ana.26291). DOI: 10.1002/ana.26291

Received Feb 8, 2021, and in revised form Dec 7, 2021. Accepted for publication Dec 19, 2021.

Address correspondence to Dr Helmich, Radboud University Medical Center, PO Box 9101, 6500 HB Nijmegen, the Netherlands.  
E-mail: [rick.helmich@radboudumc.nl](mailto:rick.helmich@radboudumc.nl)

<sup>†</sup>Martin E. Johansson and Ian G. M. Cameron contributed equally.

From the <sup>1</sup>Donders Institute for Brain, Cognition and Behavior, Center for Cognitive Neuroimaging, Radboud University, Nijmegen, The Netherlands;

<sup>2</sup>Donders Institute for Brain, Cognition and Behavior, Center for Medical Neuroscience, Department of Neurology, Center of Expertise for Parkinson and Movement Disorders, Radboud University Medical Center, Nijmegen, The Netherlands; <sup>3</sup>Donders Institute for Brain, Cognition and Behavior, Radboud University, Nijmegen, The Netherlands; <sup>4</sup>Faculty of Electrical Engineering, Mathematics, and Computer Science, University of Twente, Enschede, The Netherlands; and <sup>5</sup>Precision Health, Nutrition and Behavior, OnePlanet Research Center, Nijmegen, The Netherlands

Additional supporting information can be found in the online version of this article.

# Exercise and hippocampal volume

- Hippocampal volume shrinks by 1-2% pa in older adults without dementia
- Increases risk for cognitive impairment
- Exercise increases cerebral blood volume and hippocampal perfusion
- Exercise may increase BDNF, which mediates neurogenesis

# *Erickson et al* Aerobic exercise intervention

## Aerobic exercise


- Walking 10 mins, increasing by 5 mins until 40 mins by week 7
- HR monitors, target 50-60% max HR (220-age) for weeks 1-7, then 60-75% remainder of program
- Exercise log
- Every 4 weeks, summary provided

“79% attendance”; number of sessions per week?

Actual amount of exercise performed?



**(A) Example of hippocampus segmentation and graphs demonstrating an increase in hippocampus volume for the aerobic exercise group and a decrease in volume for the stretching control group.**



Kirk I. Erickson et al. PNAS 2011;108:7:3017-3022

PNAS



# Aerobic Exercise: Evidence for a Direct Brain Effect to Slow Parkinson Disease Progression

J. Eric Ahlskog, PhD, MD

## Abstract

No medications are proven to slow the progression of Parkinson disease (PD). Of special concern with longer-standing PD is cognitive decline, as well as motor symptoms unresponsive to dopamine replacement therapy. Not fully recognized is the substantial accumulating evidence that long-term aerobic exercise may attenuate PD progression. Randomized controlled trial proof will not be forthcoming due to many complicating methodological factors. However, extensive and diverse avenues of scientific investigation converge to argue that aerobic exercise and cardiovascular fitness directly influence cerebral mechanisms mediating PD progression. To objectively assess the evidence for a PD exercise benefit, a comprehensive PubMed literature search was conducted, with an unbiased focus on exercise influences on parkinsonism, cognition, brain structure, and brain function. This aggregate literature provides a compelling argument for regular aerobic-type exercise and cardiovascular fitness attenuating PD progression.

© 2017 Mayo Foundation for Medical Education and Research ■ Mayo Clin Proc. 2018;93(3):360-372



From the Department of Neurology, Mayo Clinic, Rochester, MN.

Parkinson disease (PD) is a relatively common neurologic condition with perhaps 1 million affected people in the United States. Increasingly, their treatment is falling into the hands of primary care physicians, who should be able to provide optimal care to most patients.<sup>1-3</sup> As previously described,<sup>2</sup> appropriate carbidopa/levodopa administration is the single most crucial medication strategy. Herein, the argument is advanced that the other important component of optimal PD treatment is engagement in regular aerobic-type exercise. Although no medications are proven to slow PD progression, there is substantial evidence for vigorous exercise attenuating PD progression, which is the specific focus of this article.

Exercise advice may be skeptically viewed by patients. The lay public is bombarded by health advice, some biologically supported and some that is arbitrary, unsupported, or commercially driven. Exercise is easily dismissed as yet another dictum from health experts. Moreover, regular exercise implies strenuous, time-consuming physical work, which for some people is novel. Thus, an exercise prescription for people with PD is easily discarded, especially in the absence of definite proof.

## IMPEDIMENTS TO CLINICAL TRIAL ASSESSMENT OF PD EXERCISE INFLUENCES

Definitive arguments for any health intervention are expected to come from clinical randomized controlled trials (RCTs). The outcome of interest is preventing the slow neurologic decline that occurs with PD. Unfortunately, a valid and reliable RCT of long-term exercise to slow PD progression is not truly feasible for several reasons.

First, PD progression tends to be very slow. Reliable and valid biomarkers of PD progression have yet to be developed. Assessment requires outcome measures that will not be contaminated by medication effects (ie, levodopa and related drugs); this precludes motor outcomes routinely used in PD clinical trials (eg, Unified Parkinson Disease Rating Scale scores). From a patient's perspective, the most important markers of clinical progression are dementia and levodopa-refractory symptoms, which are measureable and not subject to medication influences. However, these problems typically do not develop for many years or decades and, thus, are not amenable to RCTs.

Second is the physical and motivational challenge of longer-term engagement in an

# Conclusion

- ***Regular aerobic-type exercise tending to lead to fitness is the single strategy with compelling evidence for slowing PD progression***
- ***All patients with PD should be encouraged to engage in regular exercise***
- ***Optimize L-dopa Rx to enable engagement in vigorous exercise***

# Effects of Exercise on Depressive Symptoms in Patients With Parkinson Disease

A Meta-analysis

Ryul Kim, MD, Tae Lee Lee, BS, Hanall Lee, MS, Do Kyung Ko, BS, Beomseok Jeon, MD, PhD, and Nyeonju Kang, PhD

*Neurology*® 2023;100:e377–e387. doi:10.1212/WNL.0000000000201453

## Correspondence

Dr. Kang  
nyunju@inu.ac.kr

## Abstract

### Background and Objective

The purpose of this study was to provide clear evidence in support of the use of exercise to improve depressive symptoms in patients with Parkinson disease (PD) and to investigate whether this effect differs by exercise type and intensity.

### Methods

Three independent reviewers searched for randomized controlled trials (RCTs) that applied exercise interventions with depressive symptoms as an outcome measure for patients with PD on PubMed and Web of Science up to February 28, 2022. Random-effects meta-analyses were performed, in which standardized mean differences (SMDs) between the effects of exercise and control interventions on depressive symptoms with 95% CIs were calculated.

### Results

A total of 19 RCTs including 1,302 patients with PD were eligible for meta-analysis, and we obtained 23 comparisons from the included studies for data synthesis. Physical exercise interventions showed significant effects on the reduction in depressive symptoms in patients with PD (SMD = 0.829; 95% CI = 0.516–1.142;  $p < 0.001$ ). Moderator analyses on exercise type revealed significant positive effects for combined exercise interventions (SMD = 1.111; 95% CI = 0.635–1.587;  $p < 0.001$ ), whereas aerobic training alone failed to show significant effects (SMD = 0.202; 95% CI = –0.045 to 0.449;  $p = 0.108$ ). Both light-to-moderate intensity exercises (SMD = 0.971; 95% CI = 0.521–1.421;  $p < 0.001$ ) and moderate-to-vigorous intensity exercises (SMD = 0.779; 95% CI = 0.407–1.152;  $p < 0.001$ ) significantly improved depressive symptoms with a small difference between the exercise intensities.

### Discussion

Our results suggest that physical exercise has significant antidepressant effects in patients with PD. These effects seemed to be more closely associated with exercise type than intensity. Different types of exercise interventions may result in greater benefit and require further investigation.

From the Department of Neurology (R.K.), Inha University Hospital, Inha University College of Medicine, Incheon, Korea; Department of Human Movement Science (T.L.L., H.L., D.K.K., N.K.), Incheon National University, Korea; Division of Sport Science (T.L.L., H.L., D.K.K., N.K.), Sport Science Institute & Health Promotion Center, Incheon National University, Korea; Department of Neurology (B.J.), Seoul National University Hospital, Seoul National University College of Medicine, Korea; and Neuromechanical Rehabilitation Research Laboratory (N.K.), Incheon National University, Korea.

Go to [Neurology.org/N](https://www.neurology.org/N) for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.

RESEARCH ARTICLE

# Effects of physical exercise programs on cognitive function in Parkinson's disease patients: A systematic review of randomized controlled trials of the last 10 years

Franciele Cascaes da Silva<sup>1\*</sup>, Rodrigo da Rosa Iop<sup>1</sup>, Laiana Cândido de Oliveira<sup>1</sup>, Alice Mathea Boll<sup>1</sup>, José Gustavo Souza de Alvarenga<sup>2</sup>, Paulo José Barbosa Gutierrez Filho<sup>2</sup>, Lídia Mara Aguiar Bezerra de Melo<sup>2</sup>, André Junqueira Xavier<sup>3</sup>, Rudney da Silva<sup>1</sup>

**1** University of State of Santa Catarina, Center for Health Sciences and Sports, Adapted Physical Activity Laboratory, Florianópolis, Santa Catarina, Brazil, **2** University of Brasília, Faculty of Physical Education, Brasília, Brazil, **3** University of Southern Santa Catarina, Medicine Course, Florianópolis, Santa Catarina, Brazil

\* francascaes@yahoo.com.br



## Abstract

### OPEN ACCESS

**Citation:** da Silva FC, Iop RdR, de Oliveira LG, Boll AM, de Alvarenga JGS, Gutierrez Filho PJB, et al. (2018) Effects of physical exercise programs on cognitive function in Parkinson's disease patients: A systematic review of randomized controlled trials of the last 10 years. PLoS ONE 13(2): e0193113. <https://doi.org/10.1371/journal.pone.0193113>

**Editor:** Stephen D Ginsberg, Nathan S Kline Institute, UNITED STATES

**Received:** August 1, 2017

**Accepted:** February 5, 2018

**Published:** February 27, 2018

**Copyright:** © 2018 da Silva et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Data Availability Statement:** All relevant data are within the paper and its Supporting Information files.

**Funding:** The authors declare that the work has not received funding.

**Competing interests:** The authors have declared that no competing interests exist.

## Background

Given the relative importance of cognitive impairment, there was considerable interest in identifying the cognitive profile of PD patients, in order to ensure specific and appropriate therapeutic interventions.

## Purpose

To determine the effects of physical exercise programs on cognitive function in PD patients, compared with the control group.

## Data sources

Medline, Cochrane, Scopus, PEDro and Web of Science (last searched in September 2016).

## Study selection

Randomized clinical trials examining the effects of physical exercise programs and cognitive function in PD patients. Nine studies fulfilled the selection criteria and were included in this review.

## Data extraction

Characteristics of the publication, characteristics of the participants, test used for cognitive screening, cognitive domain assessed, tools used to assess cognitive function, characteristics of the experimental intervention, characteristics of the control group, mean results and standard deviation of function cognitive. The PEDro score was used to evaluate methodological quality.

# “Peripheral progression”

- Neuromuscular
- Cardiovascular
- Note- mitochondrial dysfunction
- Resistance (strength) may provide more benefits than aerobic

# Strength and physical functions in people with Parkinson's disease

Sacha Clael<sup>\*1,2,3</sup> & Lídia Bezerra<sup>1</sup>

<sup>1</sup>Faculty of Physical Education, University of Brasília, Brasília, Brazil

<sup>2</sup>Mauá Institute of Research & Education, Brasília, Brazil

<sup>3</sup>Integrated College IESGO, Formosa, Goiás

\*Author for correspondence: Tel.: +5561983837418; [sachael@hotmail.com](mailto:sachael@hotmail.com)

First draft submitted: 3 May 2019; Accepted for publication: 22 May 2019; Published online: 9 October 2019

**Keywords:** alternative therapy • exercise • neurophysiology • physical activity • resistance training

## Strength & physical functions

Strength refers to the maximum force that a muscle or muscle group can generate, and it is important to be assessed in all populations, young and old, men and women, healthy and with some type of disease. Strength is essential to perform activities of daily living and to have a good quality of life as with diminishing strength, simple tasks start to become hard [1].

Physical functions has various terms to refer it (exercise capacity, physical fitness, physical performance, physical capacity, physical ability, physical limitation, physical disability, functional status, functional capacity, functional ability, physical functional status, health status and so on). Furthermore, all these words must mean the individual's ability to function. Moreover, physical functions related with activities can be split in simple movements (e.g., stand up from a chair) and complex movements (e.g., playing soccer). To perform movements, simple or complex, it is important to have cardiorespiratory fitness, strength, muscle endurance, flexibility and balance [2].

## Physical capacities & diseases

Some diseases can alter the individual's physical capacities, such as Parkinson's disease (PD) affects the muscles, thus affecting strength. The diminishing strength in this population occurs because there is a progressive deterioration of the substantia nigra in the midbrain causing a decrease in dopamine production. This reduction in dopamine results in a GABA-mediated tonic inhibition of the thalamus, which in turn reduces the excitation of the thalamus on cortical projection areas. This is manifested as an alteration in somatic motor activities and as a result, a person with PD can have difficulties contracting the muscles, thereby reducing the strength production [3].

The diminished strength in people with PD affects their quality of life, simple tasks such as rising from a chair become difficult, as do all day-to-day tasks [4]. The deficit in central activation of muscles is responsible for muscle weakness [5]. PD affects not only motor symptoms like resting tremor, bradykinesia, freezing, gait disturbance and postural instability but also contributes to diminished maximal force production [6]. Skinner *et al.* [7] verified the effect of PD in 13 individuals and 13 controls after performing maximal and submaximum (5, 10 and 20% of maximum voluntary contractions) isometric force tasks. The results showed that PD individuals demonstrated lower strength in lower limbs when compared with controls. These results reinforce the fact that strength deficits cause impairments in activities of daily living.

The major treatment for PD is oral medication, and the main drug is the levodopa. This drug is the most effective for PD and works increasing dopamine levels in the brain, which reduces motor fluctuations. There is variation from oral levodopa, levodopa intestinal gel, but it is expensive and invasive. Also in medicaments, dopamine agonists are used as alternative that mimic dopamine effects in the brain. The monoamine oxidase inhibitors can be used to prevent the breakdown of brain dopamine by inhibiting the brain enzyme monoamine oxidase B [8]. Furthermore, anticholinergics [9], amantadine [10] and catechol O-methyltransferase inhibitors [11] are alternative medicaments for PD treatment.

# Ideal exercise for PD

## Key elements

- Aerobic; moderate and HIT
- Resistance, strength
- Stretching

*“Any exercise is good”*

*“Do exercise that interests you”*

*“Exercise is medicine”*





F.I.T.T.- V.P.	Aerobic	Strength	Balance, Agility, & Multi-Tasking	Flexibility
Frequency	At least 3 days per week.	2-3 days per week, challenging all major muscle groups on nonconsecutive days.	2-3 days per week focused workout, with daily integration as possible.	≥ 2-3 days/week, with daily being most effective.
Intensity & Progression	Moderate Intensity: 40% - 60% HRR (or VO <sub>2</sub> R), RPE of 12-13/20 or 3-4/10. <b>Progress</b> to vigorous intensity: 60-85% HRR; RPE 14-17/20 or 5-7/10), when physiologically appropriate and safe. Teach client to self-assess.	40-50% of 1-RM for beginners. 60-70% 1-RM for more advanced exercisers. <b>Progress</b> number of repetitions and resistance, working muscles to fatigue.	Appropriate challenge delivered in a safe manner given the setting (individual vs group). <b>Progress</b> motor and cognitive challenges as patient improves and can tolerate.	Full extension, flexion, or rotation stretch to the point of slight discomfort. <b>Progress</b> as patient can tolerate
Time & Volume	≥30 min of continuous or intermittent exercise per session.  Build to at least 150 minutes/week.	10-15 repetitions starting an exercise program. ≥1 set of 8-12 repetitions (~60% 1-RM) and progress to 3 sets of 8-10 to fatigue. Build to 2-3 hours/week.	30-60 minutes per workout.  Build to 2-3 hours/week.	Static Stretching: 15-60 seconds per muscle; 2-4 repetitions of each stretch.  Dynamic Stretching: 8-10 movements in each direction.
Type	Prolonged, rhythmic activities using large muscle groups.	Major muscle groups of the upper and lower body using weight machines, resistance bands, or body weight. Focus on extensors. Could use resistance training with instability.	Multi-directional stepping, weight shifting, reaching, large amplitude movements, functional agility (steps, turning, obstacles, backwards, floor activities, sit-to-stand). Multi-task training (motor, cognitive, distractions). Static and dynamic balance with varied surfaces, limb support, perturbations.	Static Stretching: All major muscle groups after exercise, first thing in the morning or before bed. Dynamic stretching/active range of motion: Prior to intense aerobic and strengthening exercise. Include diaphragmatic breathing and meditation.
Disease-Related Considerations	Prioritize safety (ambulatory status, physical assistance, equipment). Risk of freezing of gait. Consider comorbidities (e.g. musculoskeletal, cardio-respiratory). Risk of autonomic dysfunction, including orthostatic hypotension, blunted heart rate response to exercise, arrhythmias associated with PD or medications.	Posture and body mechanics. Estimate 1-RM safely. Progressive with high repetitions. Timed for ON periods of optimal functioning. For safety, avoid heavy free weights. Consider comorbidities (e.g. spinal stenosis, osteoporosis, osteopenia).	Consider varied ability levels related to cognitive engagement and attention. Allow upper extremity support when needed. Consider comorbidities (e.g. peripheral neuropathy, cognitive decline). Risk of freezing of gait. Use of gait belt for safety.	Consider dystonia (tonic or activity-induced) and general worsening of flexed posture with disease progression. Consider comorbidities (e.g. osteoporosis, pain, dystonia).
	Consider collaborating with a licensed physical therapist specializing in Parkinson's disease to assist with full functional evaluation and individually-tailored exercise recommendations taking into account complex medical history.			2021

# What if I can't exercise

- Note cardiac screening;  
Review of risk factors, symptoms,  
non-invasive testing  
GP review
- Modifications; eg chair yoga,
- Alter the mix; less cardio, more weights
- Research may identifiable injectable factors

PD and Boxing???

Muhammed Ali, Atlanta Olympics 1996

Recently clarified NOT CTE



# Rock Steady Boxing

> 43 000 participants in > 830 sites worldwide





# Boxing for Parkinson's Disease: Has Implementation Accelerated Beyond Current Evidence?

Meg E. Morris<sup>1,2\*</sup>, Terry D. Ellis<sup>3</sup>, Dana Jazayeri<sup>1,2</sup>, Hazel Heng<sup>1</sup>, Andrea Thomson<sup>1</sup>, Arun Prasad Balasundaram<sup>1</sup> and Susan C. Slade<sup>1,2</sup>

<sup>1</sup> La Trobe Centre for Sport and Exercise Medicine Research, School of Allied Health, Human Services and Sport, La Trobe University, Bundoora, VIC, Australia, <sup>2</sup> Healthscope North Eastern Centre, Ivanhoe, VIC, Australia, <sup>3</sup> Center for Neurorehabilitation, Boston University College of Health and Rehabilitation Sciences, Sargent College, Boston, MA, United States

**Background:** Exercise and physical activity are argued to promote neural plasticity in Parkinson's disease (PD), with potential to slow disease progression. Boxing for PD is rapidly growing in popularity.

**Objectives:** (i) To evaluate evidence on benefits and risks of boxing exercises for people living with PD and (ii) to appraise websites for evidence of global implementation of this intervention.

**Data Sources:** We searched AMED, CINAHL, Cochrane, EMBASE, EMCARE, Health and Medical Collection via ProQuest, MEDLINE, and PEDro electronic databases for the research literature. Websites were also searched for evidence of successful implementation of boxing for PD.

**Study Selection:** Published research and websites were considered if they reported data on adults with PD and boxing as an intervention.

**Data Extraction:** For the literature review, two reviewers independently extracted data on study characteristics and intervention content. Risk of bias was assessed with the PEDro scale and Joanna Briggs Checklist. We conducted a quality appraisal of websites using the QUality Evaluation Scoring Tool (QUEST).

**Data Synthesis:** Two studies, with a total of 37 participants, met the review eligibility criteria for the literature review. Risk of bias was low in these trials. Balance confidence, mobility, and quality of life were reported to improve with community-based boxing training programs delivered in 24–36 sessions over 12 weeks. PD medications were not always documented and some elements of the boxing interventions were incompletely reported against the CERT (Consensus on Exercise Reporting Template). Nine websites advocating boxing programs for PD were also evaluated. The QUEST analysis showed low-level quality, and little scientific evidence verifying findings, despite positive reports.

**Limitations:** In the published literature, findings were limited due to the small number of included studies and participants. Websites were numerous yet often lacked verifiable data.

## OPEN ACCESS

### Edited by:

Martina Mancini,  
Oregon Health & Science University,  
United States

### Reviewed by:

Erika Franzén,  
Karolinska Institutet (KI), Sweden  
Laurie A. King,  
Oregon Health & Science University,  
United States

### \*Correspondence:

Meg E. Morris  
m.morris@latrobe.edu.au

### Specialty section:

This article was submitted to  
Movement Disorders,  
a section of the journal  
Frontiers in Neurology

**Received:** 25 September 2019

**Accepted:** 04 November 2019

**Published:** 04 December 2019

### Citation:

Morris ME, Ellis TD, Jazayeri D,  
Heng H, Thomson A,  
Balasundaram AP and Slade SC  
(2019) Boxing for Parkinson's Disease:  
Has Implementation Accelerated  
Beyond Current Evidence?  
Front. Neurol. 10:1222.  
doi: 10.3389/fneur.2019.01222

# Many unanswered questions

- Dose, timing, intensity, optimal regimen
- Side effects
- Safety and appropriateness at different stages
- Comparison with other exercises
- Impact on disease progression
- Motor v NMS
- Sleep, mood, balance, olfaction
- How to train instructors













Michael  
J. Fox

Determined to  
outfox Parkinson's.

**OPTIMISM**

*Pass It On.*

**VALUES.COM** THE FOUNDATION  
FOR A BETTER LIFE



## ***FIGHT-PD***

# **Feasibility of Instituting Graduated High intensity Training for Parkinson's Disease Protocol for a non-contact boxing exercise study**

**David Blacker**- *medical director, neurologist, PD patient*

**Rai Fazio**- *former Australian amateur boxing champion and boxing trainer*

**Travis Cruickshank and Mitchell Turner**- *exercise physiologists*

**Claire Tucak**- *neuropsychiotherapist*

Australian and New Zealand Clinical Trial Registry Number 380492



# Objectives

1. Feasibility
2. Tolerability
3. Safety

Use principles of exercise science to quantify the components of the program

- Continual HR monitoring
- Rate of perceived physical (RPE) and mental exertion  
Borg scales
- Close monitoring for injury
- Compare standardized PD measures pre/post



< Back

POLAR



HR avg



149bpm

HR max

Calories



25%

Fat burn % of cals

## Basic & steady state training




Training Benefit

Heart rate

Fat Fit

Pace

bpm



5

4

3

2

1

00:00:00

00:08:28

00:16:02

00:16:35

00:11:20

# Scales and Questionnaires


- ♦ Baseline
- ♦ Before each exercise session
- ♦ During the exercise session
- ♦ After the exercise session
- ♦ End of 5 week block
- ♦ End of the 15 week programme

**Borg's Rating of Perceived Exertion (RPE) Scale**

Perceived Exertion Rating	Description of Exertion
6	No exertion. Sitting & resting
7	Extremely light
8	
9	Very light
10	
11	Light
12	
13	Somewhat hard
14	
15	Hard
16	
17	Very hard
18	
19	Extremely hard
20	Maximal exertion

[https://www.braininjuryaustralia.org.au/wp-content/uploads/Barry-Willer\\_2.pdf](https://www.braininjuryaustralia.org.au/wp-content/uploads/Barry-Willer_2.pdf)

# Participant Selection





# 10 subjects

- 6M, 4 F
- Ages 45-67; mean 60
- UPDRS motor;6-32  
6,7,10,14,15 and 18,24,25,25,32  
Mean 8.8 mean 24.8  
overall mean 16.6
- Sx duration < 5 years in 7
- All except one on therapy

CODE	AGE/ SEX	WEIGHT (KG)	HEIGHT (CM)	MOCA	UPDRS	BP - LAYING	BP - STANDING	SYMPTOM ONSET	DIAGNOSIS DATE	DATE OF FIRST MEDS	CURRENT PD MEDS	PD SUBTYPE	PREDOMINANT SIDEDNESS	H & Y STAGE
FPD1 - 001	65 M	87	179	30	25	175/ 86	133/ 83	2008	2010	2010	Pramipexole Stalevo	Tremor	RIGHT	2
FPD1 - 002	45 M	79	180	26	6	137/ 80	135/ 87	2015	2016	2016	Stalevo Rotigone patch	Tremor	LEFT	1
FPD1 - 003	52 M	100	182	22	25	169/ 94	137/ 76	2019	2020	2020	Pramipexole	Tremor	LEFT	1
FPD1 - 004	65 F	60	165	30	24	149/ 91	136/ 95	2016	2018	2000	Madopar	PIGD	LEFT	2
FPD1 - 005	66 F	65	154	28	18	140/ 83	123/ 85	2016	2018	N/A	Nil	PIGD	LEFT	1
FPD1 - 006	63 M	87	183	29	32	170/ 93	131/ 82	2017	2020	2020	Rasagaline	Tremor	LEFT	1
FPD1 - 007	67 F	73	167	29	15	155/95	144/ ***	2014	2015	2015	Madopar Pramipexole	PIGD	RIGHT	1
FPD1 - 008	56 F	73	175	30	14	117/ 81	88/ 71	2017	2018	2018	Madopar	Tremor	RIGHT	1
FPD1 - 009	56 M	82	183	29	7	128/ 88	127/ 88	2018	2019	2019	Stalevo Safinamide	PIGD	RIGHT	1
FPD1 - 010	65 M	81	183	30	10	125/ 90	130/ 94		2019	2019	Madopar Pramipexole	PIGD	RIGHT	1

	Familiarisation Week
	Training Weeks
	Rest Week

Training Program	W 1	W 2	W 3	W 4	W 5	W 6	W 7	W 8	W 9	W 10	W 11	W 12	W 13	W 14	W 15
	Boxers Development					Boxers Cardio					Boxers Brain				
	Physical Load		Cognitive Load			Physical Load		Cognitive Load			Physical Load		Cognitive Load		
	<70% APMHR <13 RPE		<7 RPME			>80% APMHR >15 RPE		<7 RPME			70-80% APMHR 13-15 RPE		>7 RPME		


Example Block	R1	R2	R3	R4	R5	R6	R7	R8	R9	R1 0	R1 1	R1 2
	UB	C	LB	CA	CA	Boxing						
	Boxers Movement											

W, week; APMHR, age-predicted maximum heart rate; RPE, rate of perceived exertion; RPME, rate of perceived mental exertion; R, round; APMHR, age-predicted maximum heart rate; RPE, rate of perceived exertion; RPME, rate of perceived mental exertion


# Attendance

Workouts	Subjects	Subtotal	Reason for absence
36	4	144	Not applicable
35	3	105	*1 knee strain 1 unwell post COVID-vax 1 sick pet
34	2	68	1 hospital (SAE) 1 travel issue due to COVID lockdown
31	1	31	*3 calf muscle strain 2 travel issue due to COVID lockdown
		348	348/360= 96.7% <b><u>* 4 sessions lost due to injury</u></b>

## Block 2




## Fatigue



Self-reported fatigue levels decreased as indicated by median values (orange line)

# UPDRS pre/post





# UPDRS pre/post

- 9/10 showed reduction; ie improvement
- Overall mean fell from 16.6 to 11.6
- 4/5 in baseline lower reduced, but one increased so mean remained 8.8
- All 5 in higher group reduced; mean falling from 24.8 to 14.4
- Note; -3.3 indicates “clinically meaningful” improvement

# Future FIGHTs

- Later stage PD- stage 3+ possibly targeting those requiring walking aids, focus on balance and falls reduction; discussions with OPH
- Instructional video; telehealth applications
- Rural zoom groups
- Refined short exercise program
- Comparison with other exercise, controlled for aerobic output; eg bike v boxing
- PD gymnasium; + other therapies, eg yoga

# Psychological reaction to Dx

“You have PD”

Incurable, progressive, neurodegenerative

- Shock, grief
  - Loss of future
  - Reactive depression
  - Insomnia
  - Apathy
  - Demoralization
- 
- Image of “future self” has to be revised

# Reaction could impact on progression

- Poor psychological reaction could enhance apathy, decrease motivation, decrease physical activity
- Further accelerate deterioration

## VIEWPOINT

**Melissa J. Armstrong, MD, MSc**  
McKnight Brain  
Institute, Department  
of Neurology,  
University of Florida  
College of Medicine,  
Gainesville; and  
Norman Fixel Institute  
for Neurologic  
Diseases, University of  
Florida, Gainesville.

**Michael S. Okun, MD**  
McKnight Brain  
Institute, Department  
of Neurology,  
University of Florida  
College of Medicine,  
Gainesville; and  
Norman Fixel Institute  
for Neurologic  
Diseases, University of  
Florida, Gainesville.

**Corresponding  
Author:** Melissa J.  
Armstrong, MD, MSc,  
McKnight Brain  
Institute, Department  
of Neurology,  
University of Florida  
College of Medicine,  
PO Box 100236,  
Gainesville, FL 32610  
(melissa.armstrong@  
neurology.ufl.edu),  
[melissa.armstrong@neurology.ufl.edu](mailto:melissa.armstrong@neurology.ufl.edu)

[jamanetwork.com](http://jamanetwork.com)

## Time for a New Image of Parkinson Disease

**Parkinson disease** is now the fastest growing neurological disorder globally.<sup>1</sup> An estimated 6.1 million individuals worldwide had a Parkinson disease diagnosis in 2016, 2.4-fold higher than in 1990.<sup>1</sup> The most common representation of Parkinson disease continues to be the 1886 sketch by Sir William Richard Gowers, MD, published in his book *A Manual of Diseases of the Nervous System* (Figure, A).<sup>2</sup> Other Parkinson disease images remain largely based on Gowers' famous sketch: older white men who are frail, hunched forward, and shaking.

This commonly used image fails to accurately reflect a contemporary view of Parkinson disease and the heterogeneity in age at onset, sex, race/ethnicity, and disease experience. The incidence of Parkinson disease is highest in individuals aged 70 to 79 years,<sup>3</sup> and the prevalence peaks between ages 85 and 89 years.<sup>1</sup> However, these groups are considered to be late-onset Parkinson disease (70 years or older).<sup>4</sup> In one large study,<sup>4</sup> late-onset Parkinson disease accounted for only 39% of the people with Parkinson disease compared with 51% for middle-onset Parkinson disease (aged 50 to 69 years) and 10% for young-onset Parkinson disease (younger than 50 years).

Additionally, the male predominance of Parkinson disease, while well supported, may be overemphasized. Global analyses have shown a male to female ratio of 1.4.<sup>1</sup> In a separate analysis, the incidence of Parkinson disease was statistically higher in men only in those aged 60 to 69 years and 70 to 79 years.<sup>3</sup> Overall, the incidence was 37.16 per 100 000 person-years for women and 44.21 per 100 000 person-years for men,<sup>3</sup> demonstrating that Parkinson disease is common in both sexes.

In the US, Parkinson disease is more frequently diagnosed in white non-Hispanic populations. Using 1995 and 2000 to 2005 Medicare data, the incidence ratio of Parkinson disease among black vs white individuals was 0.74 (95% CI, 0.732–0.748). The prevalence ratio was 0.58 (95% CI, 0.575–0.581).<sup>5</sup> While Parkinson disease was less commonly diagnosed in black populations, the mean (SD) prevalence was still 1036.41 (86.01) per 100 000 Medicare recipients in this group.<sup>5</sup> An accurate view of Parkinson disease must include individuals from different backgrounds.

The frailness and disability shown in Gowers' 1886 picture is also not an accurate rendering of the modern experience of people with Parkinson disease. Recent subtyping identified the disabling diffuse malignant form of Parkinson disease in only 16% of cases.<sup>6</sup> A mild motor-predominant Parkinson disease phenotype was the most common presentation (49%), followed by the intermediate form (35%).<sup>6</sup> While all phenotypes are progressive, the mean (SD)

time from diagnosis to first milestone (regular falls, wheelchair dependence, dementia, or residential/nursing home placement) was 14.3 (5.7) years for the mild motor-predominant form, 8.2 (5.3) years for the intermediate form, and 3.5 (3.2) years for the diffuse malignant form. Mean (SD) survival after diagnosis was 20.2 (7.8) years for the mild motor-predominant form, 13.2 (6.7) years for the intermediate form, and 8.1 (5.4) years for the diffuse malignant form.<sup>6</sup> This suggests that people with Parkinson disease are living for many years without the profound disability implied by Gowers' sketch. Current approaches to Parkinson disease subtyping have limitations, and consensus on optimal categorization is lacking. However, it is clear that the experiences of individuals with Parkinson disease are varied and include mild and slow disease progression.

Does it matter? Almost certainly. Images are an increasingly important part of medical teaching. However, medical textbooks continue to have biases relating to age, sex, and race/ethnicity. These biases result in inadequate and unrealistic information.<sup>7</sup> For example, based on existing research, it is possible that images emphasizing the male predominance of Parkinson disease contribute to delays in women with Parkinson disease receiving specialty care. It is similarly possible that the classic picture of advanced Parkinson disease leads to lack of recognition of early Parkinson disease symptoms, especially within primary care settings.

Images such as Gowers' figure also contribute to public assumptions that Parkinson disease is an illness of old, frail individuals. This adds to the stigma reported by people with Parkinson disease, and stigma is a significant contributor to the quality of life of people with Parkinson disease.<sup>8</sup> Research outside Parkinson disease also suggests that expectations can be a self-fulfilling prophecy: negative perceptions of aging at baseline were associated with worse gait speed, decrements in verbal fluency, and impaired self-rated memory after 2 years of follow-up.

No single image can encapsulate the range of motor and nonmotor symptoms experienced by individuals with Parkinson disease, and there is no one common path. However, it is time that our medical images reflect modern people with Parkinson disease (Figure, B-D): young and old; male and female; active and debilitated; working, retired, or disabled; and with various symptoms and circumstances. While no single image can reflect the diversity of backgrounds, phenotypes, and experiences in Parkinson disease, it is important that our images are consistent with the advances in Parkinson disease that have occurred in the more than 130 years since Gowers' sketch. Improving the image to include a broad diversity of

## From: Time for a New Image of Parkinson Disease

JAMA Neurol. 2020;77(11):1345-1346. doi:10.1001/jamaneurol.2020.2412



### Figure Legend:

Images of Parkinson Disease: 1886 and 2020A, Illustration of Parkinson disease by Sir William Richard Gowers, MD, published in his book *A Manual of Diseases of the Nervous System*. B, Individuals with mild motor-predominant Parkinson disease often present at a young age (ie, in their 50s to 60s). They have mild motor symptoms and few nonmotor symptoms, slow progression, and a good response to medications. Because of this, others may not be able to tell that the person has Parkinson disease other than the presence of tremor, mildly decreased facial expression, and sometimes foot dystonia (dotted circle). C, Individuals with the intermediate Parkinson disease phenotype have more prominent movement symptoms, including decreased facial expression, stiffness, slowness, and tremor, often with a modest response to medication. While the symptoms are more obvious than in the mild

# Problems with a stereotyped image

- 1. Diagnostic Bias
- 2. Doesn't account for important non- motor symptoms

*You don't look like you have PD!*

### PwPD

- Often feel frustrated negative about this
- “ Don't they believe me?”
- “ They think I'm not that unwell”

### Speaker

- Just trying to be supportive
- Don't know what else to say



# Main problem with image

- Trigger negative reaction and downhill path
- Self fulfilling prophecy

RESEARCH ARTICLE

# Negative Perceptions of Aging and Decline in Walking Speed: A Self-Fulfilling Prophecy

Deirdre A. Robertson<sup>1\*</sup>, George M. Savva<sup>2</sup>, Bellinda L. King-Kallimanis<sup>1</sup>, Rose Anne Kenny<sup>1,3</sup>

**1** TILDA (The Irish Longitudinal Study on Ageing), Department of Medical Gerontology, Trinity College, Dublin, Ireland, **2** School of Health Sciences, University of East Anglia, Norwich Research Park, Norwich, Norfolk, United Kingdom, **3** Trinity College Institute of Neuroscience, Trinity College, Dublin, Ireland

\* droberts@tcd.ie



## Abstract

### Introduction

Walking speed is a meaningful marker of physical function in the aging population. While it is a primarily physical measure, experimental studies have shown that merely priming older adults with negative stereotypes about aging results in immediate declines in objective walking speed. What is not clear is whether this is a temporary experimental effect or whether negative aging stereotypes have detrimental effects on long term objective health. We sought to explore the association between baseline negative perceptions of aging in the general population and objective walking speed 2 years later.

### Method

4,803 participations were assessed over 2 waves of The Irish Longitudinal Study on Ageing (TILDA), a prospective, population representative study of adults aged 50+ in the Republic of Ireland. Wave 1 measures – which included the Aging Perceptions Questionnaire, walking speed and all covariates – were taken between 2009 and 2011. Wave 2 measures – which included a second measurement of walking speed and covariates – were collected 2 years later between March and December 2012. Walking speed was measured as the number of seconds to complete the Timed Up-And-Go (TUG) task. Participations with a history of stroke, Parkinson's disease or an MMSE < 18 were excluded.

### Results

After full adjustment for all covariates (age, gender, level of education, disability, chronic conditions, medications, global cognition and baseline TUG) negative perceptions of aging at baseline were associated with slower TUG speed 2 years later ( $B = .03$ , 95% CI = .01 to .05,  $p < .05$ ).

### Conclusions

Walking speed has previously been considered to be a consequence of physical decline but these results highlight the direct role of psychological state in predicting an objective

## OPEN ACCESS

**Citation:** Robertson DA, Savva GM, King-Kallimanis BL, Kenny RA (2015) Negative Perceptions of Aging and Decline in Walking Speed: A Self-Fulfilling Prophecy. PLoS ONE 10(4): e0123260. doi:10.1371/journal.pone.0123260

**Academic Editor:** Antony Bayer, Cardiff University, UNITED KINGDOM

**Received:** July 14, 2014

**Accepted:** December 29, 2014

**Published:** April 29, 2015

**Copyright:** © 2015 Robertson et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Data Availability Statement:** Full dataset available at the Irish Social Sciences Data Archive (ISSDA) (<http://www.ucd.ie/issda/data/tilda/>), based at the UCD Geary Institute, Ireland.

**Funding:** Funding was gratefully received from the Atlantic Philanthropies ([www.atlanticphilanthropies.org/](http://www.atlanticphilanthropies.org/)), the Irish Government, the Health Research Board ([www.hrb.ie/](http://www.hrb.ie/)). TILDA is funded by the Department of Health and Atlantic Philanthropies, along with support from Irish Life in the form of a charitable gift. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. This does

# JAMA Neurology comment

- **July 28, 2020**
- **Thanks for the Image Update- I can see myself**
- **David Blacker, MB BS, FRACP | Perron Institute for Neurological and Translational Science**
- **Thanks to Armstrong and Okun for this compact, informative and timely article, co-inciding with the week of the World Federation of Neurology World Brain Day (July 22nd), which this year highlights Parkinson Disease. What we say as doctors to patients is highly impactful; words need to be chosen carefully and perceptions of illness count. I suspect that mental perception of PD may even influence progression; if a negative, nihilistic image is formed around the time of diagnosis, the self-fulfilling prophecy concept, combined with apathy, could contribute to lack of engagement in physical therapy and mobility, which I suspect accelerates progression.**



Published in final edited form as:

J Parkinsons Dis. 2012 ; 2(2): 153–160. doi:10.3233/JPD-2012-12083.

## Declining Quality of Life in Parkinson Disease Before and After Diagnosis

**Natalia Palacios,**

Department of Nutrition, Harvard School of Public Health, Boston, MA, USA

**Xiang Gao,**

Department of Nutrition, Harvard School of Public Health, Boston, MA, USA; Channing Division of Network Medicine, Harvard Medical School, Boston, MA, USA

**Michael Schwarzschild, and**

Department of Neurology, Massachusetts General Hospital, Boston, MA, USA

**Alberto Ascherio**

Department of Nutrition, Harvard School of Public Health, Boston, MA, USA; Channing Division of Network Medicine, Harvard Medical School, Boston, MA, USA

### Abstract

We sought to assess the quality of life in PD patients before the diagnosis, in comparison to age-matched individuals free of PD, among participants in two large prospective cohorts of men and women. Components of the Short-Form Health Status Survey (SF36) were administered to all participants in 1996 and 2008 in the Health Professionals Follow-up Study (HPFS), and in 1992, 1996, 2000 and 2004 in the Nurses' Health Study (NHS). We used scores in 7 health-related quality of life-dimensions, that were rated from 1(worst) to 100(best) points. We fitted a multivariate mixed-effect model with repeated measures to estimate the expected decline with age and compared that to the decline observed among PD cases by time to diagnosis. 454 men and 414 women with PD contributed data to the analyses. A decline in physical function in PD patients relative to the whole cohort began approximately 7.5 years prior to diagnosis in women and 3 years prior to diagnosis in men, and continued to decline thereafter with a rate of 2.35 and 1.43 points per year in women and men respectively ( $p < 0.001$  for both). For comparison, the average yearly decline in individuals without PD was 0.42 and 0.23 points per year in women and men respectively. Other measures of quality of life (only available in women) declined in a similar pattern to physical function. In summary, the quality of life in PD patients begins to decline years before the diagnosis.

### Keywords

Parkinson; Progression; Epidemiology; Quality of Life

### Introduction

There is growing evidence that Parkinson disease (PD) often starts with non-motor symptoms that precede the diagnosis by several years[1,2] but there are no data on the physical and social functioning of PD patients before the disease is diagnosed. In a recent study, newly diagnosed PD patients showed evidence of limitations in the UPDRS Activities

**Correspondence to:** Dr. Natalia Palacios, Department of Nutrition, Harvard School of Public Health, 665 Huntington Avenue, Boston, MA 02115, USA. Tel.: +1 617 304 4254; palacios@hsph.harvard.edu. .

# QOL before and after Dx of PD

Two large longitudinal population health studies

- Nurses Health study

121 701 women followed from 1976

- Health professionals follow up study

51 539 men from 1986

Biannual questionnaires re lifestyle, health issues

Surveys every 4 years

SF36-measures health related QOL

# Decline in QOL before Dx of PD

- Questions about Dx of PD from 1988
- 2008 analysis;

PD Dx in 454 men and 414 women

***A decline in physical function began;***


***7.5 years before PD Dx in women***

***3.0 years before PD Dx in men***


# SF 36

## WOMEN

A. Physical Function Among PD Cases by Time to Diagnosis, \*NHS




B. Relative Physical Function (Residual) of PD Cases Compared to Non-Cases of the Same Age, Gender and Smoking History by Time to PD Diagnosis, NHS




## MEN

C. Physical Function Among PD Cases by Time to Diagnosis, \*HPFS



D. Relative Physical Function (Residual) of PD Cases Compared to Non-Cases of the Same Age, Gender and Smoking History by Time to PD Diagnosis, HPFS



\*Dashed line represents physical functioning of persons of same age as the PD patients in each time-to-diagnosis strata, based on model adjusting for age in 5 year groups.

# Decline in QOL after Dx of PD

- ***Rates of yearly average decline are 5 to 7 times faster in PD, compared with non-PD matched for age and gender***
- ***QOL worse in PD than;***  
diabetes, MS, SCI, angina, depression
- ***Can this be altered?***



# What we say as doctors is highly impactful

**Don't just say;**

- See you in 6 months to consider medications
- Have some brochures
- Try to get to a newly diagnosed seminar
- *Patients want more!*

# POSSIBLE INTERVENTION

## Education

- Correct misperceptions; time course of neurodegenerative conditions, myths about L-dopa

## Support

- Early follow up
- E-mail accessibility

## Early dopamine replacement

- To optimize exercise
- Don't miss out of benefits

## Healthy lifestyle


## Exercise

## Peer group counselling

## Focus on “bucket list”


***Could actually improve!***

***“Honeymoon boost”***



## Research Article

# Positive Mental Attitude Associated with Lower 35-Year Mortality: The Leisure World Cohort Study

Annlia Paganini-Hill <sup>1</sup>, Claudia H. Kawas,<sup>1,2,3</sup> and Maria M. Corrada<sup>1,3,4</sup>

<sup>1</sup>Department of Neurology, School of Medicine, University of California, Irvine, California, USA

<sup>2</sup>Department of Neurobiology & Behavior, School of Biological Sciences, University of California, Irvine, California, USA

<sup>3</sup>Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, California, USA

<sup>4</sup>Department of Epidemiology, School of Medicine, University of California, Irvine, California, USA

Correspondence should be addressed to Annlia Paganini-Hill; [annliahi@usc.edu](mailto:annliahi@usc.edu)

Academic Editor: Carmela R. Balistreri

Copyright © 2018 Annlia Paganini-Hill et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**Background.** Although emerging research has suggested that “positive psychological well-being” is associated with better health outcomes, studies of long-term health and mortality in the elderly are limited. This study assessed the relationship of mental attitude and mortality in older adults followed up for 35 years. **Methods.** In the 1980s, the Leisure World Cohort Study recruited residents of a California retirement community to a prospective cohort study of health promotion and disease prevention. Participants completed a postal survey including seven positively worded items from the Zung self-rating depression scale. Age-adjusted and multivariable-adjusted (for lifestyle behaviors and disease conditions) hazard ratios (HRs) for death were calculated using Cox regression for 8682 women and 4992 men (median age at entry, 74 years). During follow-up (1981–2016), 13,405 participants died (median age at death, 88 years). **Results.** In both women and men, HRs for death were significantly related to mental attitude with increasing risk with decreasing positive responses for total attitude and the seven individual items. The multivariable-adjusted HR (95% CI) for death for individuals in the lowest vs. highest quarter of total attitude was 1.24 (1.16, 1.32) for women and 1.30 (1.19, 1.41) for men. Some attenuation in the observed associations occurred after adjustment for potential confounders and after elimination of the first five years of follow-up. **Conclusions.** Our study suggests that persons with negative attitude have an increased risk of death even after many years of follow-up. Research into strategies to improve mental outlook may help improve the quantity as well as the quality of life.

## 1. Introduction

The number of elderly adults continues to increase as does the need for them to lead lives in good mental and physical condition. Although “positive mental attitude,” “psychological well-being,” “life satisfaction,” and “happiness” are vague concepts, emerging research suggests that they are associated with better health outcomes [1–5] while their opposites “negative mental attitude,” “life dissatisfaction,” “pessimism,” and “depression and depressive symptoms” are associated with poorer outcomes [6–9].

Studies of mental attitude and long-term health (including mortality) in the elderly are limited by sample size

and length of follow-up. Four prospective cohort studies of all-cause mortality in the elderly have included more than 10,000 participants [10–13], and only one of these included both sexes [10]. Follow-up has been greater than 10 years in only three studies [10, 14, 15]. Thus, little is known about whether positive mental attitude has any predictive value in old age over a long-time span.

In 1981, we undertook a prospective cohort study of nearly 14,000 elderly women and men in a California retirement community with the aim of studying factors associated with longevity and successful aging. We report here the results of positive mental attitude (seven items from the Zung self-rating depression scale [16]) on all-cause mortality

# Effects of dispositional optimism on quality of life, emotional distress and disability in Parkinson's disease outpatients under rehabilitation

Annalisa Gison, MD<sup>a</sup>  
Federica Rizza, PhD<sup>a</sup>  
Stefano Bonassi, PhD<sup>b</sup>  
Valentina Donati, PhD<sup>a</sup>  
Salvatore Giaquinto, MD<sup>a</sup>

<sup>a</sup> Department of Neurological Rehabilitation, IRCCS San Raffaele Pisana, Rome, Italy  
<sup>b</sup> Unit of Clinical and Molecular Epidemiology, IRCCS San Raffaele Pisana, Rome, Italy

Correspondence to: Annalisa Gison  
E-mail: annalisa.gison@sanraffaele.it

## Summary

This study was performed with the aim of assessing dispositional optimism (DO) in a sample of Parkinson's disease (PD) patients, in order to evaluate its association with clinical outcomes and its impact on rehabilitation.

Before entering an outpatient rehabilitation program, 58 participants suffering from idiopathic PD completed the Life Orientation Test-Revised (LOT-R) to evaluate their level of DO, the WHO-5 scale to evaluate their health-related quality of life (HR-QoL), the Hospital Anxiety and Depression Scale (HADS) to identify emotional distress, and the Barthel Index to evaluate their level of disability.

All the measures were repeated four months later, at their discharge from the program. Disease stage and severity measures (Unified Parkinson's Disease Rating Scale) were also taken into consideration. Correlations and multivariate regression analyses compared DO with the health-related variables.

On admission a high level of DO was found to be associated with less severe disease, a better quality of life (QoL) and lower emotional distress, but not with level of disability (Barthel Index). Consistent results were found at discharge. The level of DO did not change after rehabilitation, while anxiety was significantly reduced, especially in subjects with low LOT-R and high HADS scores. The Barthel Index values significantly improved. At discharge, participants with high DO showed the best improvements in disability and in QoL.

In conclusion, a high level of DO was associated with QoL, HADS and UPDRS both on admission and at discharge. The level of DO remained stable after rehabilitation, while disability and anxiety were reduced. Participants with high DO generally had better QoL, and better clinical and psychological performances.

**KEY WORDS:** disability, dispositional optimism, mood, Parkinson's disease, quality of life, rehabilitation

## Introduction

Parkinson's disease (PD) is a disabling and progressive disease. Nevertheless, dispositional optimism (DO) has recently become a topic of growing interest and research within the field of PD. The mental attitude, or outlook on life, of individuals with DO is characterized by positive expectations and confidence in a secure future. They also view events and situations, including difficulties, in a positive light. In recent years, there has been an increase in studies exploring emotional responses, adaptive behavior and coping strategies under stressful conditions (see Chiesi et al., 2013).

Three early studies investigated the role of DO on disability and health-related quality of life (HR-QoL) in PD. While a longitudinal study in 12 PD patients found no significant relationship between disease severity and DO (Shifren, 1996), the Global Parkinson's Disease International Survey (2002) found a statistically significant effect of DO on HR-QoL in 1020 PD patients. Several years later, the presence of low DO or high pessimism was found to be associated with reduced QoL in 99 PD patients (Gruber-Baldini et al., 2009). More recently, we found high DO to be associated with a satisfactory quality of life (QoL), low emotional distress, and reduced disease severity in PD (Gison et al., 2014). None of the above studies considered the effect of rehabilitation.

The present study was conducted with two aims: i) to evaluate the presence of correlations between PD patients' levels of DO and major measures of well-being, both on admission to and at discharge from an outpatient rehabilitation program; ii) to examine the effect of baseline DO (on admission) on the rehabilitation outcome.



## Post-traumatic growth in people living with a serious medical condition and its relations to physical and mental health: A systematic review

Tatjana Barskova & Rainer Oesterreich

To cite this article: Tatjana Barskova & Rainer Oesterreich (2009) Post-traumatic growth in people living with a serious medical condition and its relations to physical and mental health: A systematic review, *Disability and Rehabilitation*, 31:21, 1709-1733, DOI: [10.1080/09638280902738441](https://doi.org/10.1080/09638280902738441)

To link to this article: <https://doi.org/10.1080/09638280902738441>



Published online: 15 Sep 2009.



Submit your article to this journal



Article views: 2394







View related articles



Citing articles: 50 View citing articles

## Article

# A Qualitative Study on the Impact of First Steps—A Peer-led Educational Intervention for People Newly Diagnosed with Parkinson's Disease

Andrew Soundy <sup>1,\*</sup>, Johnny Collett <sup>2</sup>, Sophie Lawrie <sup>2</sup>, Shelly Coe <sup>2</sup>, Helen Roberts <sup>3</sup>, Michele Hu <sup>4</sup>, Sally Bromley <sup>5</sup>, Peter Harling <sup>6</sup>, Alex Reed <sup>7</sup>, Jan Coebergh <sup>8</sup>, Camille Carroll <sup>9</sup> and Helen Dawes <sup>2</sup>

<sup>1</sup> School of Sport, Exercise and Rehabilitation, University of Birmingham, Birmingham B15 2TT, UK

<sup>2</sup> Centre for Movement, Occupational and Rehabilitation Sciences, Faculty of Health and Life Sciences, Oxford Brookes University, Oxford OX3 0BP, UK; jcollett@brookes.ac.uk (J.C.); 19003090@brookes.ac.uk (S.L.); scoe@brookes.ac.uk (S.C.); hdawes@brookes.ac.uk (H.D.)

<sup>3</sup> Academic Geriatric Medicine, University of Southampton. Southampton General Hospital Mailpoint 807, Southampton SO16 6YD, UK; H.C.Roberts@soton.ac.uk

<sup>4</sup> Department of Neurology, Nuffield Department of Clinical Neurosciences, Level 3, West Wing, John Radcliffe Hospital, Oxford OX3 9DU, UK; michele.hu@ndcn.ox.ac.uk

<sup>5</sup> Parkinson's UK Oxford Branch, Botley Women's Institute Hall, North Hinksey Lane, Oxford OX2 0LT, UK; oxford.sally@gmail.com

<sup>6</sup> Norton Consulting Group, Malthouse, Main Road, Curbridge OX29 7NT, UK; peter.harling@nortonexecutive.com

<sup>7</sup> European Parkinson's Therapy Centre. Piazzale Delle Terme, 3, 25041 Dafo Boario Terme (Brescia), Italy; alexreeditaly@gmail.com

<sup>8</sup> Department of Neurology, St George's University Hospitals NHS Foundation Trust, London SW17 0QT, UK; Jan.Coebergh@asph.nhs.uk

<sup>9</sup> Institute of Translational and Stratified Medicine, University of Plymouth, N14, ITTC Building, Plymouth Science Park, Plymouth Science Park, Plymouth, Devon PL6 8BX, UK; camille.carroll@plymouth.ac.uk

\* Correspondence: A.A.Soundy@bham.ac.uk

Received: 12 September 2019; Accepted: 3 October 2019; Published: 10 October 2019



**Abstract:** *Aim:* The dual aim of this research was to consider the impact of providing the First Steps program on the stories of people with Parkinson's Disease (PD) and to investigate the psychosocial and emotional mechanisms which may explain this impact. *Methods:* A qualitative study using a subtle realist paradigm and hermeneutic phenomenological methodology was undertaken. A single semi-structured interview was used to consider the impact and experiences of people with PD who completed either the intervention (2-day peer-led behavior intervention using storytelling 6–8 weeks apart) or received telephone support calls as part of the active control group. Descriptive statistics and a narrative analysis were undertaken on the results. *Results:* Forty-two participants were invited to participate, forty of whom completed the interview. This included 18 from the intervention group and 22 from the active control group. The intervention group identified the value of the program as worth-while, demonstrating improved exercise behavior and coping mechanisms following the intervention. Three major stories (the affirmed, the validated and the transformed story) identified the impact of the intervention. Three internal mechanisms (perceived control, hope and action, and the individual's mind set) alongside three social mechanisms (social comparison, social control and the first opportunity to share with peers) appeared to explain this impact. *Conclusion:* This study provides exciting and novel evidence of the impact of a peer-led psycho-educational intervention for people newly diagnosed with PD. Further research is needed to consider the impact of stories-based approaches on participants and consider a critical evaluation of the mechanisms which may explain changes in stories and self-reported behaviour.

# First steps Peer –led Educational Intervention for newly Dx PD

- Major problem in care of PD at Dx is lack of social support
- Educational programs important
- Some have shown improvements in self-reported mood and QOL
- Program of interviews and workshops
- Based in Oxford, UK

# ***PATH-PD Program***

**P**ositive **A**ttitude **T**owards **H**ealth

Soon after diagnosis or first visit

Session with PD nurse psychologist

Lead through package of information

Where to find support, trials, websites, books,  
video, medication advice, driving, insurance



# Can effect be measured?

- Excellent longitudinal data sets
- MJ Fox Foundation PPMI- progressive Parkinsons markers initiative
- TONiC- Trajectory of Outcome in Neurological conditions

Based in UK, started with MS and MND

Prof Sluv Koks, Perron, TONiC -PD



# Exercise-Induced Neuroprotection of the Nigrostriatal Dopamine System in Parkinson's Disease

Lijuan Hou<sup>1†</sup>, Wei Chen<sup>1,2†</sup>, Xiaoli Liu<sup>1</sup>, Decai Qiao<sup>1\*</sup> and Fu-Ming Zhou<sup>3\*</sup>

<sup>1</sup> Exercise Physiology Laboratory, College of Physical Education and Sports, Beijing Normal University, Beijing, China,

<sup>2</sup> Department of Exercise and Rehabilitation, Physical Education College, Hebei Normal University, Shijiazhuang, China,

<sup>3</sup> Department of Pharmacology, University of Tennessee College of Medicine, Memphis, TN, United States

## OPEN ACCESS

### Edited by:

Hanling Zhang,  
West Virginia University, United States

### Reviewed by:

Martin Darvas,  
University of Washington,  
United States  
Javier Blesa,  
Centro Integral en Neurociencias A.C.,  
HM CINAC, Spain

### \*Correspondence:

Decai Qiao  
decai.qiao@bnu.edu.cn  
Fu-Ming Zhou  
fzhou3@uthsc.edu

<sup>†</sup> These authors have contributed  
equally to this work.

Received: 25 July 2017

Accepted: 19 October 2017

Published: 03 November 2017

### Citation:


Hou L, Chen W, Liu X, Qiao D and  
Zhou F-M (2017) Exercise-Induced  
Neuroprotection of the Nigrostriatal  
Dopamine System in Parkinson's  
Disease.  
Front. Aging Neurosci. 9:358.  
doi: 10.3389/fnagi.2017.00358

Epidemiological studies indicate that physical activity and exercise may reduce the risk of developing Parkinson's disease (PD), and clinical observations suggest that physical exercise can reduce the motor symptoms in PD patients. In experimental animals, a profound observation is that exercise of appropriate timing, duration, and intensity can reduce toxin-induced lesion of the nigrostriatal dopamine (DA) system in animal PD models, although negative results have also been reported, potentially due to inappropriate timing and intensity of the exercise regimen. Exercise may also minimize DA denervation-induced medium spiny neuron (MSN) dendritic atrophy and other abnormalities such as enlarged corticostriatal synapse and abnormal MSN excitability and spiking activity. Taken together, epidemiological studies, clinical observations, and animal research indicate that appropriately dosed physical activity and exercise may not only reduce the risk of developing PD in vulnerable populations but also benefit PD patients by potentially protecting the residual DA neurons or directly restoring the dysfunctional cortico-basal ganglia motor control circuit, and these benefits may be mediated by exercise-triggered production of endogenous neuroprotective molecules such as neurotrophic factors. Thus, exercise is a universally available, side effect-free medicine that should be prescribed to vulnerable populations as a preventive measure and to PD patients as a component of treatment. Future research needs to establish standardized exercise protocols that can reliably induce DA neuron protection, enabling the delineation of the underlying cellular and molecular mechanisms that in turn can maximize exercise-induced neuroprotection and neurorestoration in animal PD models and eventually in PD patients.

**Keywords:** basal ganglia, dendritic spine, dopamine, glutamate, medium spiny neuron, neuroprotection, neurotrophic factor, physical activity

## INTRODUCTION

Parkinson's disease (PD) is a common, age-dependent degenerative neurological disorder caused by a severe loss of the nigrostriatal dopaminergic projection (Kish et al., 1988; Hornykiewicz, 2001; Braak et al., 2004; Kordower et al., 2013), leading to the characteristic motor deficits and symptoms including resting tremor, a slowness and paucity of movements, muscle rigidity, and postural



symptom progression, less caregiver burden and less cognitive decline (Ogih et al., 2014; Rafferty et al., 2017). It has also been reported that a 24-week Tai Chi exercise improved balance and gait function while reducing falls in PD patients (Li F. et al., 2012, 2014), although another study indicated that a 16-week Tai Chi exercise failed to produce detectable beneficial effect on the motor function in PD patients (Amano et al., 2013). Additional studies have indicated that that exercise can play an important role in slowing the physical and cognitive decline resulting from PD (Corcos et al., 2013; LaHue et al., 2016; Reynolds et al., 2016; Dipasquale et al., 2017). Physical exercise has also been reported to produce synergistic benefits with L-dopa for improving motor functions in PD patients (Kang et al., 2012).

Taken together, these clinical and epidemiological studies have provided evidence supporting the conclusion that exercise not only has a significant preventive effect on PD, but also has therapeutic value by reducing the symptoms and slowing the symptom and disease progression (Figure 1), and should be promoted to the general population, PD vulnerable population in particular (Burley et al., 2016; Jackson et al., 2016; Lauzé et al., 2016). These studies also indicate that physical exercise needs to be prescribed to PD patients and be an essential component of the treatment for PD (Ahlskog, 2011; Vina et al., 2012; Shulman et al., 2013; Bloem et al., 2015; Pedersen and Saltin, 2015; LaHue et al., 2016; Lauzé et al., 2016; Reynolds et al., 2016) (Figure 1). Indeed, the highly respected International Parkinson and Movement Disorder Society has designated exercise as an adjunct therapy for PD (Fox et al., 2011).

Although much remains to be understood, exercise's benefits for PD are likely to be mediated partly by exercise-induced improvement of the general health (e.g., increasing the cardiovascular and cerebrovascular function), the function of the

skeletal musculature and also the function of the broad motor control neural systems including cerebral motor cortices, BG, the cerebellum and the thalamus (Beall et al., 2013; Petzinger et al., 2013; Singh et al., 2014; Wang et al., 2015a,b; Alberts et al., 2016; Burley et al., 2016; Jackson et al., 2016; Shah et al., 2016). Additionally, because of the known importance of the nigrostriatal DA system and the cortico-BG circuitry in motor function, a large number of studies have examined how exercise directly affects these neural systems. Below, we will summarize and synthesize these studies, starting with describing the basic anatomy and physiology of the nigrostriatal DA system and cortico-basal ganglia circuits, likely key neural targets for exercise intervention.

## ANATOMY OF THE NIGROSTRIATAL DA SYSTEM AND THE BASAL GANGLIA

### Components of the Basal Ganglia and the Nigrostriatal DA System

The basal ganglia (BG) are a group of interconnected subcortical nuclei including the striatum, globus pallidus external segment (GPe) and internal segment (GPi), the subthalamic nucleus (STN), the substantia nigra pars compacta (SNc), and pars reticulata (SNr) (Gerfen and Bolam, 2017; Zhou, 2017) (Figures 2A,B). In primates, the striatum comprises the caudate nucleus and putamen. The striatum is the major input nucleus for the BG receiving glutamatergic inputs from motor and somatosensory cortices and other cortical areas (Deng et al., 2015) and the thalamus (Smith et al., 2014). The GABAergic medium spiny neurons (MSNs), comprising 90% of the striatal neurons, are the projection neurons of the striatum and critical to

